2014 Swedish Cancer Institute (SCI)

Transcription

Step Inside and Discover
Personalized Medicine at the
Swedish Cancer Institute
SCI ANNUAL REPORT 2014
Executive Council
Thomas D. Brown, M.D., MBA
Executive Director, SCI
Todd A. Barnett, M.D.
Radiation Oncology Services
Patricia L. Dawson, M.D., Ph.D.
Patient Experience Improvement
Philip J. Gold, M.D.
Clinical Research
Eileen M. Johnston, M.D.
North SCI Network
Henry G. (Hank) Kaplan, M.D.
Hematology/Oncology Services
Christine A. Lee, M.D.
East SCI Network (SMG)
John M. Pagel, M.D., Ph.D.
Hematologic Malignancies
Eric Vallières, M.D., FRCSC
Surgery
Jim Yates, MSPH, MBA
Vice President for Operations, SCI
Selin Demir
Project Manager/Ex Oficio Member
(not pictured)
Welcome to the Swedish Cancer Institute (SCI) and its
2014 Annual Report.
Throughout its history, SCI has been
a leading pioneer and advocate in the
fight against cancer. As a non-university
research practice, we focus our resources
on advancements that will make a meaningful difference for our patients and their
families. A few examples are worth noting.
l
p
Ex
ise
e rt
•
• As an early participant in the International
Early Lung Cancer Action Program
(I-ELCAP) study, SCI helped establish the
role of low-dose CT scan screening for
individuals at high risk for lung cancer
•SCI has become an international leader
in robotic surgical resection of prostate
cancer, and recently established
ground-breaking initiatives in hyperthermic
intraperitoneal chemotherapy (HIPEC) and
irreversible electroporation (IRE)
Science • Res
ear
ch
• With 6,000 patients participating in cancer
clinical trials during the last 10 years
alone, SCI is home to one of the most active National Cancer Institute-sponsored
clinical trials programs in the United States
Cli
ni
ca
Since 1932, SCI has been a beacon of hope to thousands of
patients from throughout the Pacific Northwest and beyond.
From the early days of radiation therapy, when SCI had one of
the first super-voltage X-ray machines in the nation, to today’s
highly sophisticated next generation gene sequencing (NGS)
technologies, SCI has steadfastly pursued new approaches to
cancer prevention, diagnosis, treatment and survivorship.
•
SCI is a national leader in fully integrating
conventional and naturopathic medicine
as a means of leveraging multiple disciplines to better support a patient’s battle
against cancer and journey of survivorship
vo
rsh
ip
Personalized
Medicine
at SCI
r
vi
Educ
ation
•
Supp
ort
•
Su
•
SCI was the first in the Pacific Northwest
to install both CyberKnife® and Gamma
Knife® stereotactic radiosurgery platforms
under one roof, giving physicians and
patients convenient access to alternative
forms of focused radiation therapy
This history of leadership represents more
than eight decades of exponential growth
and development at SCI, leading us to our
current strategic focus on personalized
medicine. Today the SCI network of
distributed expertise makes our tradition
of “extraordinary care and extraordinary
caring” available to patients in communities
throughout Washington and the Pacific
Northwest.
Through this year’s annual report, you
will experience the promise of the SCI
legacy — one of hope and health for the
present and future of our patients and their
families.
www.swedish.org/cancer
1
Personalized
Medicine at the
Swedish Cancer
Institute
Executive Director
The past year has been an exciting
and transformational time for the
Swedish Cancer Institute (SCI). We
have completed a comprehensive
strategic planning process, begun
implementation of elements of the
plan, including the Personalized
Medicine Program (PMP) and the
Robert and Jean Reid Family Innovative Therapeutics & Research
Unit (ITU), and recruited key
providers within a programmatic
context.
In our strategic construct at SCI, personalized
medicine has a dual meaning:
1. Caring for the whole patient, to include
addressing patient and family socioeconomic, psychological, environmental
and supportive care needs
2
2. Utilizing molecular (gene, protein, epigenetic) information from the patient or
his or her tumor to address cancer risk,
prevention, screening, early and accurate
diagnosis, treatment of disease and
survivorship
2014 ANNUAL REPORT
The Promise of
Gene Sequencing
Through CellNetix Pathology & Laboratories,
the PMP 68-item, gene-alteration panel
has been available since March 2014 for
molecular pheno-typing of tumors. Many
SCI providers have utilized this panel in
caring for their patients.
The Personalized Medicine Research
Program (PMRP) protocol was approved
by the Swedish Institutional Review Board
(IRB) and patient registration began in
September 2014. Participation in this
protocol will allow for the collection of
tumor molecular pheno-type information,
along with clinical, laboratory and imaging
information, for three distinct purposes:
1. Prioritizing standard therapy options
for individual patients
2. Identifying relevant clinical trials for
individual patients
3. Data mining de-identified information
for research purposes
Relevant to this effort, we are finalizing the
selection of the necessary translational
research informatics platform that will help
in the collection, storage and analysis of the
PMRP data. Over the next three years we
will expand accrual to the PMRP protocol in
a stepwise fashion in order to offer all new
patients from throughout the SCI network
participation in this protocol. Our team will
re-evaluate the PMRP panel at least every
six months, with appropriate modification
of panel contents, including the addition of
relevant NGS (next generation sequencing)
and non-NGS technology tests.
Supportive Care
While the PMP panel represents the
technology-based expertise of our
Personalized Medicine Program, our
supportive care services offer the holistic
care approach that gives the true meaning
to personalized medicine. SCI has 18
supportive care services, some of which
are undergoing important programmatic
evolution.
One example of this evolution is in palliative
care, which has historically been a
hospital-based consult service offered
through the Swedish Medical Group (SMG)
hospitalist practice. For most SCI patients,
however, their palliative care needs are
centered in the outpatient realm. For this
reason, we are developing an outpatientfocused palliative care program. In a joint
recruitment with SMG, we hired Dr. Ellyn
Lee to be the medical director of the SCI
Palliative Care Program. Dr. Lee comes to
us from the University of Arizona Cancer
Center, where she was director of Palliative
Care, as well as director of the Palliative
Care Fellowship program at the Arizona
Health Sciences Center. This new palliative
care program will extend out to all practice
sites within the SCI Network, and represents
an important emphasis on quality of life
through amelioration of the symptoms
and side effects associated with cancer
and its treatment.
Ellyn M. Lee, M.D.
Recruiting to Enhance
and Expand Services
The SCI strategic plan is predicated on
broad programmatic growth, especially in
the context of our nine multi-disciplinary
disease-site teams. Three recent recruitments represent important leadership roles
within this context.
Dr. Joseph Sniezek has joined the Head
& Neck Cancer Surgery group, as medical
Continued.
Joseph C. Sniezek, M.D.
While the PMP panel represents the technology-based
expertise of our Personalized Medicine Program, our
supportive care services offer the holistic care approach
that gives the true meaning to personalized medicine.
3
director of Endocrine Surgery at the SCI,
having served in the U.S. Army Medical
Corps, most recently at Tripler Army
Medical Center, in Honolulu, Hawaii. Dr.
Sniezek has expertise in micro-vascular
surgery and flap reconstruction, along with
expertise in management of endocrinologic
head and neck cancers and related
disorders, including salivary gland, thyroid
and parathyroid malignancies. Dr. Sniezek
has initiated tumor boards and clinics
focused on thyroid and parathyroid
malignancies and related disorders.
In partnership with Swedish Medical
Group’s Swedish Surgical Specialists
(SSS), SCI hired Dr. Evan Ong as the new
medical director for Surgical Oncology,
with a focus on the management of
pancreaticobiliary and hepatic cancers.
Dr. Ong will also be leading programs in
HIPEC (Hyperthermic Intraperitoneal
Chemotherapy) and NanoKnife® (electroporation). As a national thought leader
in these new technologies, he brings
unparalleled expertise to the Pacific
Northwest. Through Dr. Ong’s experience
and leadership, we will continue to develop
the cancer surgery portfolio at the SCI
and throughout Swedish Health Services
(SHS). This will include SCI’s already strong
disease-site cancer surgery programs
(Colorectal Surgery, Breast Surgery,
Gynecologic Oncology Surgery, Head &
Neck Surgery and Thoracic Surgery), and
SHS-based surgical programs, such as
urology, liver resection and transplantation
within the Swedish Organ Transplant
Program, neurosurgery at Swedish
Neuroscience Institute, and Orthopedic
Surgery at the Swedish Orthopedic Institute.
Lastly, the new Hematologic Malignancies
program at SCI is led by Dr. John Pagel,
who has had a distinguished career at
the University of Washington and Fred
Hutchinson Cancer Research Center.
Dr. Pagel is nationally and internationally
recognized as a leader in the management
of lymphomas and leukemias, including
hematopoietic stem-cell transplantation.
Dr. Pagel is developing a designated
4
Evan S.K. Ong, M.D., M.S.
team of physicians and other health-care
professionals, focused on the care of
patients with multiple myeloma, lymphomas,
leukemias, myelo-dysplastic syndromes
and related disorders. This multi-disciplinary
and multi-professional team will also work
to expand our existing autologous hematopoietic stem-cell transplantation program.
Dr. Pagel is beginning this important initiative
with Dr. Michael Milder and Dr. Raya
Mawad, and is also pursuing additional
recruitments. I am confident that this team
will rapidly become recognized throughout
the United States and beyond for its
expertise and contributions to advancing
the care of patients with hematologic
malignancies and related conditions.
Reid Family Innovative Therapeutics and
Research Unit at SCI, on the fourth floor of
the Arnold Pavilion, is intended to provide
a state-of-the-art early-phase clinical trials
unit. This unit will be specifically focused
on molecularly targeted investigational
therapies, within the context of all of the
services that constitute the SCI Personalized
Medicine Program. With the tremendous
support of our community and the annual
Celebrate Swedish Gala in 2014, we have
raised more than $4 million to support the
development of this unit, with an anticipated
total expense of $9 million. Schematic
design of the project is under way, with
project completion anticipated by the fall
of 2015.
Research Advancing
Personalized Medicine
A Foundation of Quality,
Patient-Centered Care
The Swedish Cancer Institute is a researchbased practice. Therefore, each of our
multi-disciplinary disease-site programs
requires a robust clinical research platform.
Development of the Robert and Jean
High-quality, patient-centered care is the
ultimate goal of further development of our
Personalized Medicine Program and our
disease-oriented, multi-disciplinary cancer
programs. Toward that end, we have
2014 ANNUAL REPORT
reconfigured our quality initiatives through
the formation of the SCI Quality of Cancer
Care Committee, with Dr. Ralph Aye and
Nancy Thompson, R.N., M.S., AOCNS,
serving as co-chairs. The charge of this
committee is to “support the SCI Network/
SHS in becoming the regionally preferred
and nationally recognized innovator and
provider of personalized, high-value cancer
care and service, using demonstrated best
practices.” This committee will report
through SCI’s executive director and the
institute’s Cancer Committee, with
coordination and collaboration with
Providence-Swedish Health Alliance
quality initiatives. Given that SCI is a
non-university research practice (i.e., a
hybrid setting), the quality benchmarking
must, by definition, include our clinical
and translational research activities. Just
as importantly, Dr. Erin Ellis is leading
an effort to create a broader vision for
survivorship services at SCI, building on the
initial services offered by Helene Geraci,
M.N., ARNP. The goal is to refine the vision
for holistic care, which is a distinguishing
Nancy Thompson, MSN, R.N., AOCNS
and Ralph W. Aye, M.D.
feature of SCI’s Personalized Medicine
Program, and define the evidence-based
use and ongoing quality assessment of
supportive care services at SCI.
High-quality, patient-centered care is the ultimate goal of
further development of our Personalized Medicine Program
and our disease-oriented, multi-disciplinary cancer programs.
As all can see, we have an ambitious
agenda that is representative of our
commitment to our patients, their families
and our greater community. I want to
recognize the contributions of our SCI
members, our colleagues throughout
SHS and Providence Health Services,
along with our wonderful Puget Sound
community. We are inspired by the present
possibilities and motivated by those we
envision for the future.
5
Growing a
ResearchBased
Hematologic
Malignancies
Program
In 2014, after a distinguished
career at the University of
Washington and Fred
Hutchinson Cancer Research
Center, John M. Pagel, M.D.,
Ph.D., joined the Swedish
Cancer Institute (SCI). As chief
of the new Hematologic
Malignancies program, Dr.
Pagel’s broad-brush goal is to
develop a formal, researchbased program that advances
state-of-the-art clinical care for
patients from throughout the
Pacific Northwest and beyond.
The program cares for patients with acute
and chronic leukemias, multiple myeloma,
Hodgkin and non-Hodgkin lymphomas,
and myelodysplastic syndromes and other
myeloproliferative disorders. In addition to
established treatments, such as autologous
stem-cell transplants, the program fosters
physician collaboration in clinical trials
that will lead to the development of novel
therapies. This close partnership between
clinical care and research is aimed at
ensuring that each patient receives the
best treatment option, whether it has
already been approved by the U.S. Food
and Drug Administration or is available
only through a clinical trial.
“Dr. Pagel brings with him a world-class
reputation for research and excellence in
patient care,” says SCI Executive Director
Thomas D. Brown, M.D., MBA. “The
Hematologic Malignancies program adds
to our existing strengths in caring for
patients with blood-based cancers and
related illnesses.”
One hallmark of the program is its integration with SCI’s Personalized Medicine
6
program, which allows the hematologic
malignancies team to develop individual
treatment options based on the genetic
fingerprint of a patient’s tumor cells, and
to ensure patients receive the supportive
care they need.
Hematologic malignancies are heterogeneous tumors. For example, there are
rarely single genetic mutations that cause
leukemia, rather there are a host of mutations. Additionally, the patho-physiology
is different in each patient, which makes
it critically important to look at the genetic
profile, determine the gene alterations and
identify the very best treatment option for
each patient. Genetic profiling facilitates
the precise and patient-unique treatment of
individuals with hematologic malignancies.
Standard chemotherapy, which can result
in cancer cells becoming resistant to
treatment, may not be the best option
for treating these types of cancer; immunotherapy, on the other hand, is ideal.
Immunotherapies, such as biologics,
engineered vaccines and monoclonal
antibodies, and T-lymphocytes, can utilize
2014 ANNUAL REPORT
Henry G. Kaplan, M.D.
the patient’s own immune system to
prevent resistance to treatment and
cancer recurrence.
While building a new multi-disciplinary
team, Dr. Pagel is also working closely
with Hank Kaplan, M.D., Raya Mawad,
M.D., and Michael S. Milder, M.D., to
expand SCI’s existing autologous hematopoietic stem-cell transplantation program.
As it grows, this program will employ
both stem-cell transplantation and cellular
therapy as additional treatment approaches
to a patient’s particular cancer and cell
mutation.
Dr. Pagel brings a wealth of expertise and
experience to SCI. He received his doctoral
degree in microbiology and molecular
genetics from University of California,
Irvine and his medical degree from Boston
University School of Medicine. Prior to
coming to SCI, he spent 15 years at
the University of Washington and Fred
Hutchinson Cancer Research Center.
Beginning in 2001, he also served as the
attending physician on the hematopoietic
cell transplantation and hematologic
Raya Mawad, M.D.
Michael S. Milder, M.D.
This close partnership between clinical care and research
is aimed at ensuring that each patient receives the best
treatment option, whether it has already been approved
by the U.S. Food and Drug Administration or is available
only through a clinical trial.
malignancy services, and as clinic attending
physician at the Seattle Cancer Care
Alliance.
He is a grant reviewer for the National
Cancer Institute, and has published in
multiple leading journals, including The
New England Journal of Medicine, Blood,
Journal of Clinical Oncology, Clinical
Cancer Research, Journal of Nuclear
Medicine, Cancer Research, Biology of
Blood and Marrow Transplantation, and
Leukemia.
“I am incredibly excited to join the team
at the Swedish Cancer Institute,” says
Dr. Pagel. “The work being done here is
life-changing for patients and I am looking
forward to developing a program that will
deliver new advancements in treatment for
patients with blood-borne cancers.”
At SCI, state-of-the-art care for patients
with hematologic malignancies is the
epitome of personalized medicine. With a
renewed focus on expanding the number
of clinical trials that explore novel
approaches, including small molecule
inhibitors and immunotherapies that use
T-cells to precisely target cancer cells,
Dr. Pagel and his team are helping to
transform the treatment of hematologic
malignancies. These advancements
have the potential to replace some of the
decades-old standard chemotherapies,
which require a “treat, then watch and
wait for recurrence” approach, with a new
standard of care that focuses on “treating
and curing” hematologic malignancies.
7
Building a Surgical Oncology Regional Resource
In 2014, the Swedish Cancer
Institute (SCI) took a significant
step to enhance an already substantial surgical service for cancer
patients. While recognizing the
importance of general surgical
services for many cancer patients,
SCI is continuing to develop
specialized cancer surgery services
provided by surgical oncologists.
At the core of this effort was the recruitment and
subsequent hiring of Evan S.K. Ong, M.D., M.S., to
help consolidate existing resources into SCI’s new
Surgical Oncology Division. In tandem, SCI made
a significant financial commitment to procure the
required state-of-the-art technology to fulfill its goal
of building a regional surgical oncology resource.
Evan S.K. Ong, M.D., M.S.
8
“Our goal is to be a resource for more of the complex
surgeries, as well as the orphan diseases that
account for a very small number of procedures each
year and are very difficult to treat,” says Dr. Ong.
“For example, although few patients present with
cancers that have metastasized to the intraperitoneal
lining of the abdominal cavity, we now have highly
sophisticated procedures that can produce good
outcomes without relying on a standard course of
chemotherapy alone.”
2014 ANNUAL REPORT
Dr. Ong brings to SCI his vast experience
in the management of hepato-biliary and
pancreatic cancer, and with highly advanced
procedures, such as Hyperthermic
Intraperitoneal Chemotherapy (HIPEC),
Irreversible Electroporation (IRE) using
NanoKnife™ and Isolated Limb Infusion
(ILI) for patients with intransigent melanoma.
Dr. Ong established the HIPEC program at
the University of Arizona Medical Center.
This procedure, which has been in limited
use for many years, has been shown to
be highly effective in carefully selected
patients. It has been used to successfully
treat intraperitoneal cancer that has
metastasized from primary colorectal
cancer, ovarian cancer, gastric cancer,
appendiceal cancer or from mesothelioma
and pseudomyxoma peritonei. After
debulking the tumor, and with the patient
still in the operating room, the surgeon
“washes” the abdominal cavity with a
heated sterile solution that contains a
chemotherapeutic agent. The treatment
allows the chemotherapy to be absorbed
locally, thus killing the cancer cells at
the microscopic level and reducing the
side effects associated with standard
chemotherapy.
NanoKnife is a minimally invasive procedure
that is used to treat small, soft-tissue tumors
that cannot be removed surgically due to
their location or the patient’s condition,
and for which chemotherapy or irradiation
are not good treatment options. Using IRE
technology, NanoKnife delivers a series of
high-voltage electrical bursts to the tumor,
which destroys the tumor’s membrane.
NanoKnife is able to precisely target the
tumor, while avoiding damage to the
surrounding tissue and structures.
Isolated Limb Infusion (ILI) is a limb-sparing
procedure for patients with melanoma or
other cancers that are isolated to a limb,
but are not treatable with surgery. Using
a tourniquet to isolate the limb, high-dose
chemotherapy is delivered directly to the
limb. ILI is another procedure that eases the
strain on the patient’s body, and reduces
the toxicity and the resulting side effects
associated with standard chemotherapy. At
this time, SCI is one of only a few cancer
centers in the United States that offers ILI.
Dr. Ong brings to SCI his vast experience in the
management of hepato-biliary and pancreatic cancer, and
with highly advanced procedures, such as Hyperthermic
Intraperitoneal Chemotherapy (HIPEC), Irreversible
Electroporation (IRE) using NanoKnife™ and Isolated Limb
Infusion (ILI) for patients with intransigent melanoma.
As Dr. Ong evaluates existing resources
and builds a surgical oncology team, he
is also looking to the future. His goal is to
provide advanced surgical oncology procedures not only at Swedish First Hill, but
also at Swedish’s Edmonds and Issaquah
campuses. Dr. Ong will encourage the
surgical oncology team to pursue a new
standard of care through clinical research
into new devices and technologies.
“I bring a unique outlook to my surgical
practice,” says Dr. Ong, who is board
certified in both surgery and hospice and
palliative care. “Surgical advancements have
given us many sophisticated technologies
and SCI has the skilled surgeons to use
them. That said, our first obligation is to
determine whether a surgical option will
have a beneficial outcome for the patient.
That is where personalized medicine and
the armamentarium of surgical procedures
merge. Individual considerations ensure
surgical treatment will produce the best
possible quality of life for each individual
patient.”
9
Advancing
the Mission of
Swedish’s Brain
Tumor Center
10
Charles S. Cobbs, M.D.
In the summer of 2013,
Charles S. Cobbs, M.D.,
assumed leadership responsibilities for The Ben & Catherine
Ivy Center for Advanced Brain
Tumor Treatment (Ivy Center).
Dr. Cobbs’ title as the Dr. Greg
Foltz Endowed Director pays
tribute to the center’s founding
director.
Dr. Cobbs, who is a neurosurgeon and
internationally recognized expert in brain
cancer treatment and research, has
contributed to revolutionary discoveries
in the understanding of brain cancer,
including an influential breakthrough that
posed the possibility that brain tumors
may be caused by a virus. Consequent
research laid the foundation for new studies
throughout the United States. Following
up on this work, Dr. Cobbs is now working
toward a clinical trial that will look at
targeted antiviral therapy, which may have
benefits for patients with glioblastoma.
The Ivy Center, which is affiliated with both
the Swedish Neuroscience Institute and
the Swedish Cancer Institute, was founded
with a mission to combine research science
with medical treatments to advance the
field of brain cancer and to give new hope
to each person diagnosed with the disease.
When it first opened in 2008, the Ivy Center
became the first community-based brain
tumor treatment facility of its kind in the
Pacific Northwest. Today, it is one of the
premier brain tumor treatment centers in
the country.
Looking forward, Dr. Cobbs sees a period
of dramatic increase in clinical trials for
patients with brain tumors, including innovative surgical techniques during which the
patient is awake and stereotactic-guided
surgeries, both of which require advanced
brain mapping capabilities. Additionally, he
hopes to initiate a clinical study that could
provide the ultimate in personalized cancer
treatment. The intent is to isolate the stem
cells in a sample of a patient’s tumor cells.
The stem cells would then be transferred
to multiple dishes where they would grow.
Each dish of cells would be treated with
a different FDA-approved drug regimen.
The theory is that this approach might
be able to identify the drug regimen that
has the greatest potential to produce the
best outcome for that individual patient.
Glioblastoma will be the first brain cancer
involved in this clinical trial. The study
could be expanded to include other brain
tumors in the future.
“With the expertise of our team and our
cutting-edge lab, we are able to take
advantage of the efficiencies of a private
institution to more quickly advance the
knowledge of brain tumors and their treatments,” says Dr. Cobbs. “The Ivy Center
is well-positioned to spearhead innovation
and to develop algorithms for brain tumor
treatments. In so doing, the Ivy Center will
be setting the standard for brain tumor
centers across the country.”
2014 ANNUAL REPORT
Thyroid Biopsy
Clinic Offers
Ultimate
Convenience
The new Swedish Cancer
Institute (SCI) Neck Mass and
Thyroid Nodule Biopsy Clinic,
which opened to patients in
2014, offers one-stop, one-day
diagnostics — the ultimate in
convenience for patients with a
palpable neck mass or thyroid
nodule. Convenience, however,
is not the only benefit for
patients. The clinic’s unique
approach to diagnosing neck
masses also reduces the anxiety
patients often experience when
they must wait days or weeks
between a biopsy and learning
the results.
The development of this new service was
made possible with the recruitment of
Joseph C. Sniezek, M.D., as medical
director of Head & Neck Endocrine Surgery
at Swedish Head & Neck Surgery/SCI.
The clinic is also an example of a patientfocused service that directly benefits from
the close partnership that exists between
the Swedish Medical Center, the Swedish
Cancer Institute (SCI) and CellNetix
Pathology, which supports the clinic with
an on-site pathologist.
The clinic’s approach to diagnosing neck
masses is the first of its kind in the Pacific
Northwest.
“With just one call, email or referral through
Epic, a physician’s patient is taken care
of,” says Dr. Sniezek. “With the exception
of neck masses suspicious for lymphoma,
which require more time-consuming flow
cytometry, we have designed our service to
provide a surgical consultation, ultrasound
examination, ultrasound-guided fine needle/
core biopsy procedure, and cytopathology
review during a single patient visit in a single
location.”
Clinic providers and staff collaborate with
referring endocrinologists, oncologists and
primary-care providers to determine the
most appropriate treatment plan and a
follow-up schedule that includes the entire
treatment team. All patients with thyroid or
parathyroid malignancy are presented
at the Swedish Thyroid/Parathyroid
multidisciplinary conference, which brings
together SCI’s extensive clinical expertise,
state-of-the-art resources and novel surgical
techniques.
To provide even more convenience, SCI
plans to expand access to this “one-stopshopping” experience by eventually offering
Neck Mass and Thyroid Nodule Biopsy
clinics at both Swedish First Hill and
Swedish Issaquah campuses.
11
Expanding
Palliative Care
to Address
Growing
Outpatient
Needs
For years, palliative care
services throughout the
health-care enterprise focused
on inpatient care and the
terminally ill. Today, palliative
care has taken on a different
look as it realigns services to
meet the needs of patients
who are suffering from
advancing chronic conditions.
This is particularly applicable
to cancer patients, who often
receive much of their care on
an outpatient basis and may
live longer with cancer.
According to the American Cancer
Society’s Cancer Facts & Figures 2014,
“approximately 13.7 million Americans
with a history of cancer were alive on Jan.
1, 2012. Some of these individuals were
cancer free, while others still had evidence
of cancer and may have been undergoing
treatment.” The ACS also reports “the fiveyear survival rate for all cancers diagnosed
between 2003 and 2009 is 68 percent,
up from 49 percent in 1975-77.” These
statistics require that we carefully evaluate
palliative care services and how those
services support patients throughout their
disease trajectory.
This year, the Swedish Cancer Institute
(SCI) took a pro-active step in realigning
palliative care services by partnering with
the Swedish Medical Group to hire Ellyn
M. Lee, M.D., who is board certified in
internal geriatric medicine, as well as
hospice and palliative medicine. Dr. Lee’s
duties include medical director of Palliative
Care. She brings to Swedish extensive experience in the field of palliative medicine,
most recently as director of Palliative Care
at the University of Arizona, which included inpatient and outpatient components,
and the Hospice and Palliative Medicine
Fellowship program.
“This is a wonderful opportunity to broaden
the scope of palliative care services in
order to serve a wider population through
an outpatient program,” says Dr. Lee.
While Dr. Lee is building a program to
support all disciplines, her work with SCI
is focusing on cancer patients through
symptom management. These patients
have a complex set of spiritual, physical
and emotional needs that require very
specific services. They require coordination
of care to address high utilization of
medical services, help with quality-of-life
issues, limitations caused by their illness
or navigating family dynamics.
Dr. Lee says the approach with cancer
patients is not on ‘how much time do I
have left,’ but rather ‘how can I improve
12
Ellyn M. Lee, M.D.
my time left,’ which can be very reassuring
for patients and can also drive the type
and scope of palliative-care visits. It is
also quite natural for palliative care to view
the patient and his or her family as a unit
of treatment, which acknowledges that
cancer directly affects both the patient and
the patient’s family members.
The five-to-seven year goal is to build on
existing resources to create palliative-care
clinics at each of the Swedish campuses,
beginning with Swedish First Hill. Each
clinic will be staffed by a team of palliativecare specialists, including a physician,
nurse practitioner, registered nurse, social
worker, chaplain and administrator. Each
team member plays a specific, yet integrated, role in helping patients navigate
their disease and in providing coordination
of their ongoing care.
“SCI is a natural home for outpatient
palliative-care services,” says Dr. Lee.
“Personalized medicine is giving our
cancer patients the best care through
both science and individualized humanistic
approaches.”
2014 ANNUAL REPORT
Ralph W. Aye, M.D.
Nancy Thompson, MSN, R.N., AOCNS
Quality Brings Meaning and Value to SCI’s Mission
In today’s health-care environment, a commitment to
providing high-quality care is a
reflection of how an institution
embraces evidence-based
best practices.
In his charge to the Swedish Cancer Institute (SCI) Quality of Cancer Care Committee, Thomas D. Brown, M.D., MBA,
executive director of SCI, said, “Nothing is
more important to the mission of SCI than
providing quality care to our patients and
their families. It brings meaning and value
to what we do, regardless of the campus or
clinic at which we provide care.”
With the full support and resources of SCI
leadership, the committee has refined its
charter with the specific goal of positioning
SCI as a national and international leader
of quality in cancer care and research.
It has also moved forward with multiple
initiatives, including the development of a
scorecard of quality measures for 2015,
and is actively engaged in preparing for
certification through the Quality Oncology
Practice Initiative (QOPI) of the American
Society of Clinical Oncology (ASCO), a
national benchmark to which all cancer
programs strive to achieve. The latter
initiative will build on the QOPI certification
already earned by SCI Edmonds.
“There are many quality improvement
initiatives currently under way throughout
Swedish Health Services,” says Ralph W.
Aye, M.D., medical chairman of the
committee. “We intend on closely integrating
with the Swedish Quality and Patient Safety
Committee to benefit from their hard work,
to avoid duplication and to further develop
quality initiatives for cancer care.”
SCI’s breast cancer program is one example
of this program-based quality initiative that
the committee supports. The program
is actively pursuing accreditation by the
National Accreditation Program for Breast
Centers, which is administered by the
American College of Surgeons (ACS). This
type of accreditation acknowledges the
evidence-based best practices that are
inherent in SCI’s breast cancer program.
Medical Oncology at Swedish First Hill
also has a program-based quality initiative
to improve patient wait times, and Head &
Neck Surgery has implemented a care
coordination program to enhance the patient
experience through better coordination
of services.
The committee’s foremost objective is to
define, initiate and promote best practices
in clinical cancer care. To foster their
adoption, the committee intends to oversee
initiatives that will integrate nationally
recognized best practices with the enterprise-wide electronic medical record,
organizational operations and resource
utilization. Acknowledging that quality
and safety are interwoven, the committee
has also been charged with developing,
promoting and monitoring safety initiatives.
Developing the appropriate infrastructure
and measurement metrics will facilitate a
transparent reporting mechanism.
“SCI has a long-standing tradition of
providing high-quality, safe care,” says
Nancy Thompson, R.N., MSN, AOCNS,
clinical director of quality and performance,
and administrative chairwoman for the
committee. “As a committee and an
institution, we are committed to a neverending process of defining and evaluating
the quality of cancer care we provide
throughout the SCI Network.”
13
Critical Research at a
Non-University Cancer Institute
The Swedish Cancer Institute
(SCI) is one of the nation’s
leading research sites for
clinical trials that evaluate
novel therapies, new technologies, and approaches to
screening, diagnosing and
treating cancer. Just a few
examples of how clinical trials
at SCI are advancing the
knowledge base for cancer
care include: research into
stem-cell and targeted antiviral
therapies, which may benefit
patients with glioblastoma; a
phase II clinical trial of a PARP
inhibitor used in combination
with chemotherapy for patients
with ovarian cancer or with
BRCA mutations; and the
ongoing lung cancer screening
research in partnership with
the International Early Lung
Cancer Action Program
(I-ELCAP).
In August 2014, SCI was one of only two
non-university cancer institutes invited
to be part of the Academic Breast Cancer
Consortium (ABRCC). SCI has joined the
cancer research programs at the University
of Colorado, the University of Southern
California, the University of Arizona, the
University of New Mexico, Northwestern
University, Emory University, and University
of Texas MD Anderson Cancer Center in
this innovative research model designed to
rapidly complete clinical trials and expedite
the availability of drugs that target all
breast cancers and produce fewer side
effects than existing cytotoxic drugs.
“This is a great opportunity for SCI’s
clinical research program,” says Hank
Kaplan, M.D., SCI medical oncologist and
representative to ABRCC. “Our extensive
clinical trials program and our commitment
to gene sequencing (and in the near future
scriptome sequencing, proteomics and
metabolomics) as a means of identifying
the best available therapies make SCI a
logical partner with university-based cancer
research institutions. This is an exciting
time for SCI and for our patients who may
benefit from this new association.”
Henry G. Kaplan, M.D.
14
2014 ANNUAL REPORT
SCI Personalized Medicine
Research Program Gains
IRB Approval
In early fall 2014, the Swedish Investigational
Review Board (IRB) approved the research
component of SCI’s Personalized Medicine
Program. Enrollment in the program has
commenced. The Personalized Medicine
Research Program (PMRP) protocol further
enhances SCI’s Personalized Medicine
Program by allowing for the collection of
tumor molecular phenotypic information,
along with clinical, laboratory and imaging
information from consenting patients in
order to:
1.Prioritize standard therapy options
2.Identify relevant clinical trials
3.Allow data-mining of de-identified
information for research purposes
The principal investigators include Thomas
Brown, M.D., MBA, SCI executive director;
Anna Berry, M.D., scientific director for
SCI’s Personalized Medicine Program
and director of molecular pathology at
CellNetix; Charles Drescher, M.D., a
gynecologic oncologist with SCI’s partner
Pacific Gynecology Specialists; and Philip
Gold, M.D., leader of SCI’s Clinical
Research program.
Building on a history of translational research
at Swedish that has grown out of a close
collaboration among SCI, CellNetix, the
Swedish Neuroscience Institute (SNI) and
the Swedish Center for Research and
Innovation, the PMRP will facilitate the
exploration of treatment options that
produce the best possible outcomes
based on the results of DNA and RNA
sequencing, along with proteomic and
epigenetic profiles, and other relevant biologic parameters. This valuable information
will assist physicians in developing highly
personalized treatment plans for their
cancer patients. The PMRP may also help
fuel the introduction of new therapies into
the market place.
Participation in the PRMP will be offered to
all patients who meet the eligibility requirements, regardless of insurance status, at
SCI’s sites at Swedish Ballard, Swedish
Cherry Hill, Swedish Edmonds, Swedish
First Hill, Swedish Issaquah, SNI, Minor &
James Clinic, and the Radiation Oncology
clinic at Highline Medical Center in Burien,
Wash. The plan is for the PMRP panel to
be offered to all new patients presenting
to the SCI, at the beginning of their clinical
course. It is anticipated that this goal will be
reached within 36 months.
Anna B. Berry, M.D.
“Cancer care has evolved. Today, we are
able to take a highly personalized approach
using a tumor’s molecular fingerprint to
assist in determining the most appropriate
interventions for a particular patient,” says
Dr. Brown. “Attaining this level of information is the foundation of our Personalized
Medicine Program. At SCI, however, we
are proud of our expanded view of personalized medicine. We have interwoven
this highly sophisticated medicine with
Continued.
Charles W. Drescher, M.D.
15
Left to right: Philip J. Gold, M.D.; Patra K. Grevstad, R.N., M.N.; and Desiree Iriarte, CCRC
our long-standing tradition of caring for
the whole patient. Just as SCI was the first
cancer institute in the Pacific Northwest to
incorporate naturopathic medicine as an
integral part of cancer care, we have been
leaders in our commitment to providing
holistic care that ensures our patients’ socioeconomic, psychological, environmental and
integrative medicine needs are met.”
radiation therapy, chemotherapy, immunotherapy and molecularly targeted therapy)
to improve outcomes and enhance quality
of life. Because our physicians are clinicians
first and foremost, they are intimately
aware of where there are current gaps
in effective therapies and where new
approaches to cancer care could benefit
their patients.”
At any given time, SCI has more than 100
clinical trials under way. This essential
component of cancer research involves
more than 75 physician specialists and
nurses, and 34 dedicated research staff.
According to Dr. Brown, the Robert and
Jean Reid Family Innovative Therapeutics
and Research Unit at SCI, which is due
to open by the fall of 2015, will provide
a state-of-the-art clinical research unit to
serve our patients and their families. This
unit will support both the scientific and
holistic care aspect of personalized
medicine at SCI.
“We have a long history of clinical trials
testing new devices and medications,”
says Dr. Gold. “We have been at the
forefront of some of the most significant
breakthroughs, and leaders in testing
drugs that are now considered standard
of care, such as paclitaxel, trastuzumab,
bevacizumab, cetuximab and oxaliplatin.
We have also participated in numerous
clinical trials that evaluate the value of
combining modalities (e.g., surgery,
16
The growth of SCI’s research program
and its contributions to the diagnosis
and treatment of cancer spans decades.
The program’s steadfast pursuit of more
effective therapies is helping propel cancer
care along innovative new pathways in the
ultimate quest for a cure.
2014 ANNUAL REPORT
Improving Access to Oncology
Care and Clinical Trials
In August 2014, the National
Cancer Institute’s Community
Oncology Research Program
(NCORP) awarded the Pacific
Cancer Research Consortium
a five-year grant worth $6.9
million to improve access to lifesaving cancer care and clinical
trials across a five-state region.
NCORP is a national network of investigators, cancer-care providers, academic
institutions and other organizations. The
Pacific Cancer Research Consortium is
led by three primary sites: the Swedish
Cancer Institute (SCI), which is serving as
the grant’s fiduciary, Providence Portland
Medical Center in Oregon and St. Luke’s
Mountain States Tumor Institute in Boise,
Idaho. The consortium also includes 37
other clinical care sites in Alaska, California,
Idaho, Oregon and Washington. With
access to clinical trials a critical component
of high-quality cancer care, the consortium’s goal is to bring clinical trials and
care to individuals in metropolitan and
rural communities throughout the region
and beyond. Improving access to clinical
trials will expand the evidence base of new
therapies, which, in turn, will contribute
to improved outcomes and reduction in
cancer disparities.
“NCORP allows our medical community
the opportunity to offer our patients the
latest clinical trials,” says Gary Goodman,
M.D., one of the three primary-site
principal investigators who are providing
leadership for the program and for their
respective institutions. “It also allows us to
continue supporting critical NCI initiatives,
such as increasing access to cancer trials
in underserved communities and further
researching methods for optimizing cancer
care.”
Gary W. Goodman, M.D.
The NCI Community Oncology Research Program (NCORP)
is a national network of investigators, cancer care providers,
academic institutions and other organizations. The overall
goal of NCORP is to bring cancer clinical trials (cancer
control, prevention, screening, treatment and imaging), as
well as cancer care delivery research (CCDR), to individuals
in their own communities, thus generating a broadly
applicable evidence base that contributes to improved
patient outcomes and a reduction in cancer disparities.
17
Donors Fund SCI’s Innovative
Therapeutic and Research Unit
Cancer care and hope walk
hand in hand. Specialists at
the Swedish Cancer Institute
(SCI) provide hope to patients
and their families by identifying
courses of treatment that will
achieve the best possible
outcomes. Although less
visible to patients, generous
members of the community
also play an important role in
that hopeful process.
SCI is the largest clinical provider of cancer
care in the Pacific Northwest and has
been a leader in the advancement of new
therapies and treatment techniques since
its inception in 1932. During that time, SCI
has earned the support of individuals and
corporations who also want to see cancer
care transformed and patient outcomes
improved. In late 2013, the Robert and
Jean Reid Family Foundation allocated $2
million, from a larger gift, to SCI to support
the creation of a new state-of-the-art facility
for clinical trials. Expected to open in fall
2015, the Robert and Jean Reid Family
Innovative Therapeutics and Research Unit
(Reid Family ITU) at SCI will include:
• An expanded infusion center, including a
new Innovative Therapeutics Unit, which
will provide dedicated space for earlyphase clinical trials
•A
translational lab to handle the increased
number of blood and fluid samples
needed for each patient during the
administration of clinical trials
• A specialty pharmacy to support the
increased and specialized chemotherapy
and investigational therapy preparation
• A dedicated family lounge, which will
be available to patients, as well as their
families and caregivers, while they are at
SCI receiving treatment
Building on the momentum of the transformational gift from the Reid Family Foundation, generous members of the community
donated an additional $1.9 million for
the Reid Family ITU during the annual
fund-raising gala, Celebrate Swedish, in
April 2014. In addition to the Reid Family
Foundation, CellNetix Pathology & Laboratories, Swedish Cancer Institute Medical
Oncology Group, Tumor Institute Radiation
Oncology Group, and Barbara and Dr. Joe
Buchman provided leadership gifts that
will help make the Reid Family ITU a reality.
The Reid Family ITU will help SCI expand
its clinical research program and enhance
its search for new therapies. Paired with
SCI’s clinical expertise, the community’s
generosity funds the discovery of cancer
treatments and provides our patients with
the hope and healing they need.
SCI Physicians and Staff
Support the Reid Family ITU
In addition to the generous donors from
the community, the following members of
the Swedish family pledged their financial
support to the Reid Family ITU.
Dr. and Mrs. George R. Birchfield
Aliki Birkenbuel
Dr. and Mrs. Thomas D. Brown
Andy Case and Ralph Fateiger
Linda Cole
Drs. Patricia L. Dawson and Donna H. Kerr
Dr. Dorcas Dobie
Darlene Fanus
Rhonda Jack
Sandra S. Johnson
Cindy and Joe Kearney
Dr. Mary Kelly and Tom Kelly
Barbara Kollar
Karen McInerney
David Shepard
Dr. Tanya Wahl
Mr. and Mrs. Jim Yates
Swedish Thoracic Surgery
Dr. Ralph W. Aye
Dr. Alexander S. Farivar
Dr. Jed A. Gordon
Dr. Brian E. Louie
Joelle Thirsk
Dr. Eric Vallières
Kathy Witmer
SCI Medical Oncology Group
(First Hill)
Dr. Erin D. Ellis
Dr. Mehmet F. Fer
Dr. Philip J. Gold
Dr. Gary E. Goodman
Dr. Henry G. Kaplan
Dr. Raya Mawad
Dr. Michael S. Milder
Dr. Min Sung Park
Dr. Kristine J. Rinn
Dr. Howard L. (Jack) West
Jim Reid, son of Robert and Jean Reid, along with his wife Debra and
daughters Sarah and Jessica at Celebrate Swedish
18
2014 ANNUAL REPORT
Somasundaram Subramaniam, M.D.
Medical Oncology
Swedish Cancer Institute Open Research Studies
Bone Marrow
I3X-MC-JHTB A Phase 2 Study of
LY2784544 in Patients with Myeloproliferative Neoplasms
Brain
RTOG R1205 Randomzied Phase II Trial
of Concurrent Bevacizumab and ReIrradiation versus Bevacizumab Alone as
Treatment for Recurrent Glioblastoma
020221 A Phase III Clinical Trial Evaluating
DCVax-L, Autologous Dendritic Cells
Pulsed with Tumor Lysate Antigen for the
Treatment of Glioblastoma Multiforme
BR-002 A Study to Evaluate the Safety
and Feasibility of Transcranial MRI-Guided
Focused Ultrasound Surgery in the Treatment
of Brain Tumors
EF-14 A Prospective, Multi-center Trial of
NovoTTF-100A Together With Temozolomide
Compared to Temozolomide Alone in
Patients with Newly Diagnosed GBM
CA209143 A Randomized Phase IIB Open
Label Study of Nivolumab or Nivolumab in
Combination with Ipilimumab versus Bevacizumab in Adult Subjects with Recurrent
Glioblastoma (GBM)
CDX110-04 ACT IV Study: An International,
Randomized, Double-Blind, Controlled
Study of Rindopepimut/GM-CSF with
Adjuvant Temozolomide in Patients with
Newly Diagnosed, Surgically Resected,
EGFRvIII-positive Glioblastoma
CDX110-06 ReACT: A Phase II Study of
Rindopepimut/GM-CSF in Patients with
Relapsed EGFRvIII-Positive Glioblastoma
TPI-287-17 Phase 1/2 Dose-Escalation
Study of TPI 287 in Combination with
Bevacizumab Followed by Randomized
Study of the Maximum Tolerated Dose of
TPI 287 in Combination with Bevacizumab
versus Bevacizumab Alone in Adults with
Recurrent Glioblastoma
TPI-287-18 Phase 2 Dose-Escalation
Study of TPI 287 in Combination with
Bevacizumab in Adults with Recurrent
or Progressive Glioblastoma Following a
Bevacizumab-Containing Regimen
Breast
SWOG S1007 A Phase III, Randomized
Clinical Trial of Standard Adjuvant
Endocrine Therapy +/- Chemotherapy
in Patients with 1-3 Positive Nodes,
Hormone-responsive and Her2-Negative
Breast Cancer according to Recurrence
Score (RS)
SWOG S1202 A Randomized PlaceboControlled Phase III Study of Duloxetine
for Treatment of Aromatase Inhibitor
(AI)-Associated Musculoskeletal Symptoms
in Women with Early Stage Breast Cancer
SWOG S1207 Phase III Randomized,
Placebo-Controlled Clinical Trial Evaluating
the Use of Adjuvant Endocrine Therapy
+/- One Year of Everolimus in Patients with
High-Risk, Hormone Receptor-Positive
and HER2/neu Negative Breast Cancer
SWOG S1222 Fulvestrant Alone Versus
Fulvestrant and Everolimus Versus Fulvestrant, Everolimus and Anastrozole: A
Phase III Randomized Placebo-Controlled
Trial In Postmenopausal Patients With
Hormone-Receptor Positive Stage IV
Breast Cancer
ECOG E2108 A Randomized Phase III
Trial of the Value of Early Local Therapy for
the Intact Primary Tumor in Patients with
Metastatic Breast Cancer
ECOG E2112 A Randomized Phase III
Trial of Endocrine Therapy Plus Entinostat/
Placebo in Postmenopausal Patients with
Hormone Receptor-Positive Advanced
Breast Cancer
19
IR 3276 Early Lung Cancer Detection
Using Computed Tomography
IR 4634 Flight Attendant Medical Research Institute (FAMRI) International Early
Lung Cancer Action (I-ELCAP) Protocol
IR 4707 Ovarian Cancer Early Detection
Program
IR 4807 Collaborative Study on Sputum
Cytology of Lung Cancer Patients by the
Swedish Cancer Institute and VisionGate Inc
IR 5393 The Enhancing Connections
Telephone Program: A Cancer Education
Program
Gastroenterology
Daniel M. Landis, M.D., Ph.D.
Radiation Oncology
CTSU B-43 A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with
Radiation Therapy and Radiation Therapy
Alone for Women with HER2-Positive
Ductal Carcinoma in Situ Resected by
Lumpectomy
CTSU B-47 A Randomized Phase III Trial
of Adjuvant Therapy Comparing Chemotherapy Alone to Chemotherapy Plus
Trastuzumab in Women with NodePositive or High-Risk Node-Negative
HER2-Normal Invasive Breast Cancer
NSABP B-50-I (KATHERINE) A Randomized, Multicenter, Open-Label Phase III
Study to Evaluate the Efficacy and Safety
of Trastuzumab Emtansine versus Trastuzumab as Adjuvant Therapy for Patients
with HER2+ Primary Breast Cancer Who
have Residual Tumor Present Pathologically in the Breast or Axillary lymph Nodes
Following Preoperative Therapy
97517 I-SPY 2 Trial (Investigation of
Serial Studies to Predict Your Therapeutic
Response with Imaging and Molecular
Analysis 2)
CRC 09096 Clinical Value of Pre-Surgery
PEM in Patients with Newly Diagnosed
Breast Cancer
INCB 18424-268 A Randomized, DoubleBlind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine
in Subjects With Advanced or Metastatic
HER2-Negative Breast Cancer
20
SWOG S0820 A Double Blind PlaceboControlled Trial of Eflornithine and Sulindac
to Prevent Recurrence of High Risk
Adenomas and Second Primary colorectal
Cancers in Patients with Stage 0-III Colon
Cancer, Phase III
IR 5522 Institutional Registry Study of
Permanent Breast Seed Implant (PBSI) For
Early Stage Breast Cancers
SWOG 1115 Randomized Phase II Clinical
Trial of AZD6244 Hydrogen Sulfate (NSC748727) and MK-2206 (NSC-749607)
versus mFOLFOX in Patients with Metastatic
Pancreatic Cancer After Prior Chemotherapy
M12-895 Veliparib in Combination with
Temozolomide or Veliparib in Combination
with Carboplatin and Paclitaxel Versus
Placebo Plus Carboplatin and Paclitaxel in
Subjects with BRCA1 or BRCA2 Mutation
and Metastatic Breast Cancer
SWOG S1201 A Randomized Phase II Pilot
Study Prospectively Evaluating Treatment
for Patients Based on ERCC1 (Excision
Repair Cross-Complementing 1) for Advanced/Metastatic Esophageal, Gastric, or
Gastroesophageal Junction (GEJ) Cancer
M12-914 A Phase 3 Randomized, Placebo-Controlled Trial of Carboplatin and Paclitaxel With or Without the PARP Inhibitor
Veliparib (ABT-888) in HER2-Negative Metastatic or Locally Advanced Unresectable
BRCA-Associated Breast Cancer
CALGB 80702 A Phase III Trial of 6 versus
12 Treatments of Adjuvant FOLFOX plus
Celecoxib or Placebo for Patients with
Resected Stage III Colon Cancer
NBRST Prospective neo-adjuvant REGISTRY trial linking MammaPrint, Subtyping
and treatment response: Neoadjuvant
Breast Registry - Symphony Trial
PH3-01 “PRESENT”: Prevention of
Recurrence in Early-Stage, Node-Positive
Breast Cancer with Low to Intermediate
HER2 Expression with NeuVax™ Treatment
PROMIS Prospective Registry Of
MammaPrint in breast cancer patients
with an Intermediate recurrence Score
Cancer Control
CRAD001JUS226 (STOPP) A Phase II,
single arm study of the use of steroidbased mouthwash to prevent stomatitis in
postmenopausal women with advanced
or metastatic hormone receptor positive
breast cancer being treated with everolimus
plus exemestane
ECOG 1208 A Phase III Randomized,
Double-Blind Trial of Chemoembolization
with or without Sorafenib in Unresectable
Hepatocellular Carcinoma (HCC) in Patients with and without Vascular Invasion
NCCTG N1048 Neoadjuvant FOLFOX
with Selective Use of Combined Modality
Chemoradiation vs Preoperative Combined
Modality Chemoradiation for Locally
Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total
Mesorectal Excision
RTOG R1010 A Phase III Trial Evaluating
the Addition of Trastuzumab to Trimodality
Treatment Of HER2-Overexpressing
Esophageal Adenocarcinoma
A041-05 A Phase 1b, Open Label Study
of Dalantercept plus Sorafenib in Patients
with Advanced Hepatocellular Carcinoma
2014 ANNUAL REPORT
CAUY922AUS06T Phase Ib with Expansion
of Patients at the MTD Study of AUY922
and Cetuximab in Patients with KRAS WildType Metastatic Colorectal Cancer
SGI-110-03 A Phase 2 Study of SGI-110
in the Treatment of Advanced Hepatocellular Carcinoma (HCC) Subjects Who
Failed Prior Treatment With Sorafenib
XL184-309 A Phase III, Randomized,
Double-blind, Controlled Study of
Cabozantinib (XL184) vs Placebo in
Subjects With Hepatocellular Carcinoma
Who Have Received Prior Sorafenib
Genitourinary
SWOG S0931 EVEREST: EVErolimus for
Renal Cancer Ensuing Surgical Therapy, A
Phase III Study
SWOG S1216 A Phase III Randomized
Trial Comparing Androgen Deprivation
Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients
With Newly Diagnosed Metastatic Sensitive
Prostate Cancer
ALLIANCE A031201 Phase III Trial of
Enzalutamide Versus Enzalutamide,
Abiraterone and Prednisone for Castration
Resistant Metastatic Prostate Cancer
Leukemia
SWOG S0919 A Phase II Study of Idarubicin
and Ara-C in Combination with Pravastatin
for Poor-Risk Acute Myelogenous Leukemia
(AML)
AC220-007 A Phase 3 Open-label
Randomized Study of Quizartinib (AC220)
Monotherapy vs Salvage Chemo in
Subjects With FMS-Like Tyrosine Kinase
3 - FLT3-ITD Positive AML Refractory to or
Relapsed After First-line Treatment With or
Without HSCT Consolidation
CC-486-AML-001 A Phase 3, Randomized, Double-blind, Placebo-controlled
Study to Compare Efficacy and Safety of
Oral Azacitidine Plus Best-supportive Care
Versus Best Supportive Care as Maintenance Therapy in Subjects With Acute
Myeloid Leukemia in Complete Remission
Lung
SWOG S0819 A Randomized, Phase III
Study Comparing Carboplatin/Paclitaxel or
Carboplatin/Paclitaxel/Bevacizumab with
or without Concurrent Cetuximab in
Patients with Advanced Non-Small Cell
Lung Cancer (NSCLC)
SWOG S0905 A Phase I / Randomized
Phase II Study of Cediranib (NSC #732208)
Versus Placebo in Combination with Cisplatin and Pemetrexed in Chemonaive Patients
with Malignant Pleural Mesothelioma
SWOG S1206 A Dose Finding Study
Followed by Phase II Randomized, Placebo-Controlled Study of Veliparib (ABT-888)
Added Chemoradiotherapy with Carboplatin
and Paclitaxel for Unresectable Stage III
Non-Small Cell Lung Cancer (NSCLC),
(NCI Study Number 8811)
CALGB C140503 A Phase III Randomized
Trial of Lobectomy versus Sublobar
Resection for Small (<=2 cm) Peripheral
Non-Small Cell Lung Cancer
ECOG E5508 Randomized Phase III Study
of Maintenance Therapy with Bevacizumab,
Pemetrexed or Both Following Carboplatin, Paclitaxel and Bevacizumab for Advanced Stage Non-Squamous Non-Small
Cell Lung Cancer
8273-CL-0102 An Open-label, Phase 1
Dose Escalation Study of Oral ASP8273 in
Subjects with Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth
Factor Receptor (EGFR) Mutations
CALGB C90601 A Randomized DoubledBlinded Phase III Study Comparing
Gemcitabine, Cisplatin, and Bevacizumab
to Gemcitabine, Cisplatin, and Placebo in
Patients With Advanced Transitional Cell
Carcinoma
XL184-306 A Phase 3, Randomized,
Double-Blind, Controlled Trial of Cabozantinib (XL184) versus Mitoxantrone plus
Prednisone in Men With Previously Treated
Symptomatic Castration-Resistant
Prostate Cancer
Gynecologic
08059 Phase I Trial of Intraperitoneal
nab-Paclitaxel (Abraxane®) in the Treatment
of Advanced Malignancies Primarily
Confined to the Peritoneal Cavity
ISS22810034 Phase Ib with Expansion
of Patients at the MTD Study of Olaparib
plus Weekly (Metronomic) Carboplatin and
Paclitaxel in Relapsed Ovarian Cancer
Patients
Raya Mawad, M.D.
Hematologic Malignancies
21
ABI-007-NSCL-003 A Phase III, Randomized, Open-Label, Cross-Over,
Multi-Center, Safety and Efficacy Study to
Evaluate Nab-Paclitaxel (Abraxane®) as
Maintenance Treatment After Induction
With Nab-Paclitaxel (Abraxane®) Plus
Carboplatin in Subjects With Squamous
Cell NSCLC
AT13387-05 A Study of HSP90 Inhibitor
AT13387 Alone and in Combination with
Crizotinib in the Treatment of Non-small
Cell Lung Cancer (NSCLC)
CLDK378A2303 Oral LDK378 Versus
Standard Chemotherapy in Adult Patients
With ALK-rearranged (ALK-positive)
Advanced Non-small Cell Lung Cancer
Who Have Been Treated Previously With
Chemotherapy (Platinum Doublet) and
Crizotinib
D1532C00079 Selumetinib in Combination
with Docetaxel, in Patients receiving
second line treatment for KRAS MutationPositive Locally Advanced or Metastatic
Non-Small Cell Lung Cancer (Stage IIIB –
IV) (SELECT-1)
INCB 18424-266 Randomized, DoubleBlind Phase 2 Study of Ruxolitinib or
Placebo plus Pemetrexed/Cisplatin
and Pemetrexed Maintenance for Initial
Treatment of Subjects With Nonsquamous
NSCLC That Is Stage IIIB With Pleural/
Pericardial Effusion, Stage IV, or Recurrent
IR 4807 Collaborative Study on Sputum
Cytology of Lung Cancer Patients by
the Swedish Cancer Institute and VisionGate, Inc.
LCCC 1210 A Phase II Multi-Center Study
of the Tolerability of Weekly Nab-Paclitaxel
as Second Line Treatment for Elderly
Patients with Advanced Lung Cancer
ONC-003 (LUNG CARE Registry): An
Open Registry to Measure the Impact of
Adding RNA Expression Testing (myPlan
Lung Cancer) on Referral Decisions in
Newly Diagnosed Early Stage Lung
Adenocarcinoma Patients
U31287-A-U301 Patritumab (U3-1287) in
Combination with Erlotinib in EGFR Wildtype Subjects with Locally Advanced or
Metastatic Non-Small Cell Lung Cancer
(NSCLC) Who Have Progressed on at
Least One Prior Systemic Therapy
Lymphoma
NCILYMB 9177 Phase II Study of DoseAdjusted EPOCH+/- Rituximab in Adults
With Untreated Burkitt Lymphoma,
C-Myc Positive Diffuse Large B-Cell
Lymphoma and Plasmablastic Lymphoma
GS-US-313-0125 A Phase 3, Randomized,
Double-Blind, Placebo-Controlled Study
Evaluating the Efficacy and Safety of
Idelalisib (GS 1101) in Combination
with Bendamustine and Rituximab for
Previously Treated Indolent Non-Hodgkin
Lymphomas
Myelodysplastic Syndrome
MDS 14 (MEI-003) A Phase II Randomized,
Double-Blinded, Placebo-Controlled Study
of Pracinostat in Combination with Azacitidine in Patients with Previously Untreated
(IPSS) Intermediate Risk 2 or High-Risk
Myelodysplastic Syndrome (MDS)
Myeloma
C16014 A Phase 3, Randomized,
Double-Blind, Multicenter Study Comparing Oral MLN9708 Plus Lenalidomide
and Dexamethasone Versus Placebo
Plus Lenalidomide and Dexamethasone
in Adult Patients With Newly Diagnosed
Multiple Myeloma
CC-4047-MM-007 A Phase 3, Multicenter, Randomized, Open-Label Study
to Compare the Efficacy and Safety of
Pomalidomide, Bortezomib and LowDose Dexamethasone Versus Bortezomib
and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple
Myeloma
X05409 A Placebo-Controlled Study of
Oral L-glutamine and Pyridoxal-5-phosphate (Vitamin B6) for the mitigation of
Velcade-Induced Peripheral Neuropathy:
A Pilot Study
Solid Tumor, Hematologic
011 A Phase III Randomized, PlaceboControlled, Clinical Trial to Study the
Safety and Efficacy of V212 in Adult
Patients with Solid Tumor or Hematologic
Malignancy
Brian E. Louie, M.D.
Thoracic Surgery
22
Not Site Specific
UW PK Pharmacokinetics of Under-Studied
Drugs Used During Pregnancy
2014 ANNUAL REPORT
Swedish Cancer Institute 2013 Site Listing
DISEASE SITE
ANALYTIC
Breast
NONANALYTIC
TOTAL
SITE
SUBTOTAL
DISEASE SITE
ANALYTIC
NONANALYTIC
TOTAL
BREAST
Pharynx
26
6
32
1176
Thyroid
165
30
195
Tonsil
34
3
37
Other Endocrine Glands
90
82
172
288
1464
Total Breast
1464
GASTROINTESTINAL
Anus, Anal Canal,
Anorectum
30
6
36
Bile Ducts
24
7
31
Colon
182
102
Gallbladder
11
Liver
70
Total Head & Neck
593
HEMATOLOGIC MALIGNANCIES
284
Hematopoietic,
Reticuloendothelial
117
263
380
2
13
Hodgkin Disease
21
17
38
25
95
Non-Hodgkin Lymphoma
133
228
361
Total Hematologic Malignancies
Pancreas
124
24
148
Rectum/Rectosigmoid
112
38
150
Small Intestine
21
7
28
Stomach
79
22
101
Other Digestive Organs
14
6
20
Total Gastrointestinal
SITE
SUBTOTAL
779
NEURO ONCOLOGY
906
Brain/Cranial Nerves/
Spinal Cord
194
82
276
Central Nervous System
(CNS)
115
58
173
Total Neuro Oncology
GENITOURINARY
449
SARCOMA/MELANOMA
Bladder
108
33
141
Bone
15
10
25
Kidney/Renal Pelvis
160
38
198
Prostate
475
235
710
Connective and Soft
Tissue
31
14
45
Testis
19
10
29
Ureter
8
0
8
Retroperitoneum /
Peritoneum
8
2
10
Other Urinary Organs
2
0
2
Melanoma
115
37
152
Non-Melanoma Skin
15
35
50
Total Genitourinary
1088
GYNECOLOGIC ONCOLOGY
Cervix
48
41
89
Ovary
111
38
149
Uterus
230
20
250
Vagina
9
5
14
Vulva
11
15
26
Other Female Site
16
4
20
Total Gynecologic Oncology
282
THORACIC
548
HEAD & NECK
Total Sarcoma/Melanoma
Bronchus and Lung
402
149
551
Esophagus
34
10
44
Heart, Mediastinum,
Pleura
12
4
16
Thymus
13
4
17
Total Thoracic
628
OTHER
Gum & Other Parts of the
Mouth
Eye and Adnexa
6
5
11
30
6
36
Unknown Origin
45
14
59
Larynx
13
9
22
Total Other
Lip and Tongue
56
8
64
TOTAL
Major Salivary Gland
10
6
16
Nasal Cavity, Sinuses,
Middle Ear
This chart represents a manual consolidation of two separate registries, Swedish
Cancer Institute and SCI Edmonds. These registries report data separately.
15
4
19
70
4755
2052
6807
23
Bibliography
This bibliography features recent publications by Swedish Cancer Institute members and affiliated physicians (noted in bold)
in 2013 and year-to-date 2014.
Breast Cancer
Andersen MR, Thorpe J, Buist DS, Beatty JD,
Watabayashi K, Hanson N, Resta R, Chubak J,
Urban N. Cancer risk awareness and concern
among women with a family history of breast or
ovarian cancer. Behav Med. 2014 25:0. Epub
ahead of print. PubMed PMID: 25062114.
Jung S, Spiegelman D, Baglietto L, Bernstein
L, Boggs DA, van den Brandt PA, Buring JE,
Cerhan JR, Gaudet MM, Giles GG, Goodman
G, Hakansson N, Hankinson SE, Helzlsouer K,
Horn-Ross PL, Inoue M, Krogh V, Lof M,
McCullough ML, Miller AB, Neuhouser ML,
Palmer JR, Park Y, Robien K, Rohan TE, Scarmo
S, Schairer C, Schouten LJ, Shikany JM, Sieri
S, Tsugane S, Visvanathan K, Weiderpass E,
Willett WC, Wolk A, Zeleniuch-Jacquotte A,
Zhang SM, Zhang X, Ziegler RG, Smith-Warner
SA. Fruit and Vegetable Intake and Risk of
Breast Cancer by Hormone Receptor Status.
J Natl Cancer Inst. 2013 3(105):219-36. Epub
2013 Jan 24.
Kaplan HG, Atwood MK, Malmgren JA.
Treatment Related Breast Cancer Disease
Specific Survival Improvement Over Time Limited
to Estrogen Receptor Negative Patients:
1990-2004. Ca Res. 2013 73(8) Suppl 1:133.
DOI:10.1158/1538-7445.AM2013-133.
Kaplan HG, Malmgren JA. The Breast Cancer
Overdiagnosis Conundrum. Ann Int Med. 2013
158:60-62.
Kaplan HG, Malmgren JA, Atwood MK. Adjuvant
Chemotherapy and Differential Invasive Breast
Cancer Specific Survival in Elderly Women. J
Geriatric Onc. 2013 4:148-156. DOI:10.1016/j.
jgo.2012.12.007
Malmgren JA, Atwood MK, Kaplan HG. Triple
Negative Breast Cancer Survival in Women 75
years and older. J Clin Oncol. 2013 31(15S):1060.
Malmgren JA, Atwood, MK, Kaplan HG. Age
Related Change in Breast Cancer Stage at
Diagnosis Relative to Increased Mammography
Detection Over Time: 1990-2012. J Clin Oncol.
2014 32(15S, Part I):1589.
Malmgren JA, Parikh J, Atwood MK, Kaplan
HG. Improved Prognosis of Breast Cancer in
Women Age 75 and Older with Mammography
Detection. Radiology. 2014 Aug 5:140209.
Epub ahead of print.
Miller CP, Thorpe JD, Kortum AN, Coy CM,
Cheng WY, Ou Yang TH, Anastassiou D, Beatty
JD, Urban ND, Blau CA. JAK2 expression is
associated with tumor-infiltrating lymphocytes and
improved breast cancer outcomes: implications
for evaluating JAK2 inhibitors. Cancer Immunol
Res. 2014 2(4):301-6.C.
Park JW, Liu MC, Yee D, DeMichele A, van ’t
Veer L, Hylton N, Buxton M, Chien AJ, Wallace
A, Melisko M, Boughey J, Tripathy D, Kaplan H,
Nanda R, Chui S, Albain MK, Moulder S, Elias
A, Lang J, Edmiston K, Northfelt D, Euhus D,
Khan Q, Lyandres J, Davis S, Yau C, Sanil A,
Esserman L, Berry D. Neratinib Plus Standard
Neoadjuvant Therapy for High-Risk Breast
Cancer: First Efficacy Results From the I-Spy 2
Trial. 2014 AACR #CT227.
Phillips M, Beatty JD, Cataneo RN, Huston J,
Kaplan PD, et al. Rapid Point-Of-Care Breath Test
for Biomarkers of Breast Cancer and Abnormal
Mammograms. PLoS One 2014 9(3):e90226.
DOI:10.1371/journal.pone.0090226.
Rugo HS, Olopade, O, DeMichele A, van’t Veer,
L, Buxton M, Hylton N, Yee D, Chiefn AJ, Wallace
A, Kaplan H, Lyandres J, Davis S, Sanil A, Berry
D, Esserman L. Veliparib/Carboplatin Plus Standard Neoadjuvant Therapy for High-Risk Breast
Cancer: First Efficacy Results From the I-Spy 2
Trial. 2013 SABCS S5-02.
Ryu RJ, Eyal S, Kaplan HG, Akbarzadeh A, Hays
K, Puhl K, Easterling TR, Berg SL, Scorsone KA,
Feldman EM, Umans JG, Miodovnik M, Hebert
MF. Pharmacokinetics of Doxorubicin in Pregnant
Women. Cancer Chemother Pharmacol. 2014
73(4):789-797.
Wang CL, Eissa MJ, Rogers JV, Aravkin AY,
Porter BA, Beatty JD. (18)F-FDG PET/CTpositive internal mammary lymph nodes:
pathologic correlation by ultrasound-guided
fine-needle aspiration and assessment of
associated risk factors. Am J Roentgenol. 2013
200(5):1138-44.
Yau C, Wolf DM, Sanil A, Chien J, Wallace A,
Boughey J, Yee D, Tripathy D, DeMichele A,
Nanda R, Chiu S, Isaacs C, Albain K, Kaplan
H, Moulder S, Viscusi R, Northfelt D, Edmiston
K, Elias A, Styblo T, Haley B, Brown-Swigart L,
Flynn S, Kirst GI, Buxton M, Hylton N, Paoloni
M, Fraser Symmans F, Esserman L, Berry D, Liu
MC, Park JW, van’t Veer L. Mammaprint High1/
High2 Risk Class as a Biomarker of Response in
Neratinib Plus Standard Neoadjuvant Therapy for
Breast Cancer in the I-Spy 2 Trial. 2014 SABCS
P3-06-29.
Yee D, Haddad T, Albain K, Barker A, Benz C,
Buxton M, Chien A, DeMichele A, Dilts D, Elias A,
Kaplan HG, Malmgren JA, Calip GS, Li C. MDS/
AML Risk Post-Breast Cancer and Association
with Age: SEER data 2001-2009. J Clin Oncol.
2013 31(15S):554.
Kaplan H, Malmgren J, DeRoos A. Risk of
MDS/AML Post Radiation Treatment for Breast
Cancer: Analysis of SEER Data 2001-2009.
Breast Ca Res Treat. 2013 137:863-867.
DOI:10.1007/s10549-012-2386-9.
Kaplan HG, Malmgren JA, Li C, Calip GS. Age
Related Risk of Myelodysplastic Syndrome and
Acute Myeloid Leukemia Among Invasive Breast
Cancer Survivors: Analysis of SEER Data 20012009. Breast Cancer Res Treat. 2013; 142:629636. DOI:10.1007/s10549-013-2773-x.
Kaplan HG, Malmgren JA, Atwood MK.
Decreased Need for Adjuvant Chemotherapy
Treatment Related to Mammography Detection
of Breast Cancer in Women Age 65-74. 2013
SABCS P2-04-01.
Kaplan HG, Malmgren JA, Atwood MK. Survival
of Stage III and IV Breast Cancer Patients From
an Institutional Cohort: 1990-2007. 2014 SABCS
PE-13-05.
24
Claire Buchanan, M.D., (center) and
Katelin Pedemonte, BSN, R.N. (right)
Breast Surgery
2014 ANNUAL REPORT
Haluska P, Hogarth M, Hu A, Hytlon N, Kaplan
H, Kelloff G, Khan Q, Lang J, Leyland-Jones B,
Liu M, Nanda R, Northflet D, Olopade O, Park J,
Parker B, Parkinson D, Pearson-White S, Pusztai
L, Symmans F, Rugo H, Tripathy D, Wallace A,
Wholley D, van’t Veer L, Berry D, Esserman L.
Adaptive Trials in the Neoadjuvant Setting: A
Model to Safely Tailor Care While Accelerating
Drug Development. J Clin Oncol. 2013 30:
4584-4586.
Gastroenterological Cancer
Bastawrous A. Ischemic Bowel Disease. BMJ
Point of Care. Update 2014.
Billingham RP, Bastawrous AL. Chronic Anal
Pain. In: Complexities in Colorectal Surgery.
Steele, S.R., Maykel, J.A., Champagne, B.J.,
Orangio, G.R. editors. 2014.
Hakkarainen TW, Dellinger EP, AlfonsoChristancho R, Bastawrous A, et. al. NonSteroidal Anti-Inflammatory Drugs and the Risk
of Anastomotic Failure: A Report from Washington State’s Surgical Care and Outcomes
Assessment Program (SCOAP). JAMA Surg.
2014 Forthcoming.
Hochster HS, Messersmith WA, O’Neil BH,
Groshen SG, Lenz HJ, Cohen DJ, Denlinger
CS, Gold PJ, Eckhardt SG, Locker GY, Ames
P, McKinley M, Leichman LP. The MEK inhibitor
selumetinib ([SEL], AZD6244, ARRY-142886)
plus irinotecan (IRI) as second-line therapy for
KRAS-mutated (KRASm) metastatic colorectal
cancer (CRC). J Clin Oncol. 2013 31(suppl;
abstr 3587).
Louie S, Ely B, Lenz H, Albain K, Gotay C,
Coleman D, Raghavan D, Shields AF, Gold P,
Blanke C. Higher area under the curve and
reduced capecitabine clearance in elderly
patients with advanced colorectal cancer (SWOG
0030). Br J Cancer. 2013 109(7):1744-1749.
Morgan DR, Torres J, Sexton R, Herrero R,
Salazar-Martinez E, Greenberg ER, Bravo LE,
Dominguez RL, Ferreccio C, Lazcano-Ponce
EC, Meza-Montenegro MM, Peña E, Peña R,
Correa P, Martinez ME, Chey WD, Valdivieso
M, Anderson GL, Goodman GE, Crowley JJ,
Baker LH. Risk of Recurrent Helicobacter pylori
Infection 1 Year After Initial Eradication Therapy
in 7 Latin American Communities. JAMA.
2013 Feb;309(6):578-86. PubMed PMCID:
PMC3697935.
Rossi D, Bastawrous A. Hemorrhoids. In:
Colorectal Surgery. Bailey, Billingham, Stamos,
Snyder, editors. 2013.
Simianu VV, Bastawrous AL, Billingham, RP, et.
al., Addressing the Appropriateness of Elective
Colon Resection for Diverticulitis: A Report from
the SCOAP CERTAIN Collaborative. Ann Surg.
2014 Forthcoming.
Umamaheswaran P, Bradley DD, Bastwarous
A, Schembre D, Kratz R, Cervera-Servin
JA, Aye RW, Louie BE. Over The Scope Clip
(Otsc) Placement for Perforation, Fistula and
Anastomotic Leak Closure. Surg Endosc. 2014
Forthcoming.
Umamaheswaran P, Bastawrous AL. Abdominal
Surgical Approached to Rectal Prolapse. Curr
Prob Surg. 2014 Forthcoming.
Zhu AX, Gold PJ, El-Khoueiry AB, et al. Firstin-man Phase 1 Study of GC33, a Novel
Recombinant Humanized Antibody against Glypican-3, in Patients with Advanced Hepatocellular
Carcinoma. Clin Cancer Res. 2013 19:920-928.
Genitourinary Cancer
Brasky TM, Darke AK, Song X, Tangen CM,
Goodman PJ, Thompson IM, Meyskens FL Jr,
Goodman GE, Minasian LM, Parnes HL, Klein
EA, Kristal AR. Plasma Phospholipid Fatty
Acids and Prostate Cancer Risk in the
SELECT Trial. J Natl Cancer Inst. 2013
Aug;105(15):1132-1141. Epub 2013 Jul.
Cheng TY, Goodman GE, Thornquist MD,
Barnett MJ, Beresford SA, Lacroix AZ, Zheng
Y, Neuhouser ML. Estimated intake of vitamin D
and its interaction with vitamin A on lung cancer
risk among smokers. Int J Cancer. Epub 2014
Mar 13.
Hu J, Treat E, Porter J, et al. Technique and
Outcomes of Robot-assisted Retroperitoneoscopic Partial Nephrectomy: A Multicenter
Study. Eur Urol. Epub 2014 May 21.
James AC, Lee F, Harris WP, Cheng HH, Zhao
S, Gore JL, Lin DW, Porter MP, Yu EY, Wright JL.
Role of Maximal Endoscopic Resection Before
Cystectomy for Invasive Urothelial Bladder
Cancer. Clin Genitourin Cancer. 2014 12(4):
287-291.
Kristal AR, Darke AK, Morris JS, Tangen CM,
Goodman PJ, Thompson IM, Meyskens FL
Jr, Goodman GE, Minasian LM, Parnes HL,
Lippman SM, Klein EA. Baseline Selenium
Status and Effects of Selenium and Vitamin
E Supplementation on Prostate Cancer Risk.
J Natl Cancer Inst. 2014 106(3):djt456. DOI:
10.1093/jnci/djt456. Epub 2014 Feb 22.
Kristal AR, Till CA, Song X, Tangen CM, Goodman
PJ, Neuhouser ML, Schenk JM, Thompson IM,
Meyskens FL, Goodman GE, Minasian LM,
Parnes HL, Klein EA. Plasma Vitamin D and
Prostate Cancer Risk: Results from the Selenium
and Vitamin E Cancer Prevention Trial. Cancer
Epidemiol Biomarkers Prev. Epub 2014 Apr 14.
Lee F, Harris WP, Cheng HH, Shenoi J, Zhao S,
Wang J, Champion T, Izard J, Gore JL, Porter
MP, Yu EY, Wright J.L. Pathologic Response
Rates of Gemcitabine/Cisplatin vs. Methotrexate/
Vinblastine/Adriamycin/Cisplatin Neoadjuvant
Chemotherapy for Muscle Invasive Urothelial
Bladder Cancer. Adv Urol. 2013 317190.
Lee D, Montgomery D, Porter J. Concurrent
transperitoneal repair for incidentally detected
inguinal hernias during robotically assisted radical prostatectomy. Urology. 2013 82(6): 1320-2.
Mossanen M, Lee F, Cheng HH, Harris W, Shenoi
J, Zhao S, Wang J, Champion T, Izard J, Gore
JL, Porter MP, Yu EY, Wright J.L. Nonresponse to
Neoadjuvant Chemotherapy for Muscle-Invasive
Urothelial Cell Carcinoma of the Bladder. Clin
Genitourin Cancer. 2014 12(3):210-213.
Patel M, Porter J. Robotic retroperitoneal
surgery: a contemporary review. Curr Opin Urol.
2013 23(1)51-6.
Patel M, Porter J. Robotic retroperitoneal partial
nephrectomy. World J Urol. 2013.
Amir Bastawrous, M.D., MBA
Colorectal Surgery
Zhao S, Yu EY. Castrate Resistant Prostate
Cancer: Post-Docetaxel Management. Curr
Opin Urol. 2013 23(3): 201-207.
Zhao S, Nelson PS. Leveraging the Species
Barrier to Advance Cancer Therapy. Nat Genet.
2013 45(7):718-20.
Zhao S, Coleman I, Coleman R, Nelson PS.
PARP inhibitors attenuate docetaxel resistance
by suppressing a tumor microenvironment-associated secretory program (abstract #e22212).
ASCO. 2013.
Gynecological Cancer
Andersen MR, Sweet E, Lowe KA, Standish LJ,
Drescher CW, Goff BA. Dangerous Combinations: Ingestible CAM Supplement Use During
Chemotherapy in Patients with Ovarian Cancer.
J Altern Complement Med. 2013 Aug;19(8):71420. DOI:10.1089/acm.2012.0295. PubMed
PMCID: PMC3731675.
Drescher CW, Shah C, Thorpe J, O’Briant K,
Anderson GL, Berg CD, Urban N, McIntosh MW.
A Longitudinal Screening Algorithm that Incorporates Change Over Time in CA125 Levels Identifies Ovarian Cancer Earlier than a Single Threshold Rule. J Clin Oncol. 2013 Jan 20;31(3):387-92.
DOI:10.1200/JCO.2012.43.6691. PubMed
PMCID: PMC3732015.
Emerson RO, Sherwood AM, Rieder MJ,
Guenthoer J, Williamson DW, Carlson CS,
Drescher CW, Tewari M, Bielas JH, Robins HS.
High-throughput sequencing of T cell receptors
reveals a homogeneous repertoire of tumor-infiltrating lymphocytes in ovarian cancer. J Pathol.
Epub ahead of print 2013 Sep 11.
25
Gyurkocza B, Gutman J, Nemecek ER, Bar M,
Milano F, Ramakrishnan A, Scott B, Fang M,
Wood B, Pagel JM, Baumgart J, Delaney C, Maziarz RT, Sandmaier BM, Estey EH, Appelbaum
FR, Storer BE, Deeg HJ. Treosulfan, Fludarabine
and 2 Gy Total Body Irradiation Followed by
Allogeneic Hematopoietic Cell Transplantation in
Patients with MDS and AML. Biol Blood Marrow
Transplant. 2014 20(4):549-555.
Lionberger JM, *Pagel JM, Sandhu VK, Xie
H, Shadman M, Mawad R, Boehm A, Dean C,
Shannon-Dorcy K, Scott BL, Deeg HJ, Becker
PS, Hendrie PC, Walter RB, Ostronoff F, Appelbaum FR, Estey EH. Outpatient Bendamustine
and Idarubicin for Upfront Therapy of Elderly
AML/MDS: A Phase I/II Study using an Innovative Statistical Design. Brit J Haematol. Epub
ahead of print 2014 Apr 18. *Shared first author.
Matesan M, Rajendran JG, Press OW, Pagel
JM, Oliveira G, Maloney DG, Storb R, Cassaday
RD, Achid GR. 90Yttrium Ibritumomab Tiuxetan
Therapy in Allogeneic Transplantation in B-cell
Lymphoma with Extensive Marrow involvement
and Chronic Lymphocytic Leukemia: Utility of
Pre-transplantation Biodistribution. Nuc Med
Comm. Forthcoming.
and Christine Tiu, PA-C
Head and Neck Surgery
Head and Neck Oncology
Hong SS, Yheulon CG, Sniezek JC. Salivary
gland surgery and medical malpractice. Otolaryngol Head and Neck Surg. 2013 148(4):589-594.
Hong SS, Yheulon CG, Wirtz E, Sniezek JC.
Otolaryngology and Medical Malpractice: A
review of the past decade (2000-2011). The
Laryngoscope. 2014 124:896-901.
Klem C, Sniezek JC, Moore B, et al. Microvascular reconstructive surgery in Operations Iraqi
and Enduring Freedom: the US military experience performance free flaps in a combat zone.
J Trauma Acute Care Surg. 2013 75(2-Suppl
2):S228-S232.
Ruhl DS, Sheridan MF, Sniezek JC. Papillary
thyroid carcinoma in a branchial cleft cyst without a thyroid primary: navigating a diagnostic
dilemma. Otolaryngol. 2013 Article ID 405342.
Hematology
Budde LE, Zhang MM, Shustov AR, Pagel JM,
Gooley TA, Oliveira GR, Chen TL, Knudsen NL,
Roden JE, Kammerer BE, Frayo SL, Warr TA,
Boyd TE, Press OW, Gopal AK. A phase I study
of pulse high-dose vorinostat (V) plus rituximab
(R), ifosphamide, carboplatin, and etoposide
(ICE) in patients with relapsed lymphoma. Brit J
Haematol. 2013 161(2):183-191.
Byrd JC, Pagel JM, Awan FT, Forero A, Flinn
IW, Deauna-Limayo D, Spurgeon S, Andritsos
LA, Gopal AK, Leonard J, Eisenfeld A, Bannink
J, Stromatt S, Furman RR. A phase 1 study
evaluating the safety and tolerability of otlertuzumab, an anti-CD37 mono-specific ADAPTIR
therapeutic protein in chronic lymphocytic
leukemia. Blood. 2014 123(9):1302-1308.
Cassady RD, Guthrie KA, Budde EL, Thompson
L, Till BG, Press OW, Chauncey TR, Pagel JM,
Petersdorf SH, Bensinger WI, Holmberg LA,
Shustov A, Green DJ, Libby EN, Maloney DG,
Gopal AK. Specific Features Identify Patients
with Relapsed/Refractory Mantle Cell Lymphoma
26
Benefitting from Autologous Hematopoietic Cell
Transplantation. Biol Blood Marrow Transplant.
2013 19(9):1403-1406.
Chow V, Dorcy KS, Sandhu R, Gardner K, Becker
P, Pagel J, Hendrie P, Abkowitz J, Appelbaum
F, Estey E. Evaluation of early discharge after
hospital treatment of neutropenic fever in acute
myeloid leukemia (AML). Leuk Res Rep. 2013
2(1):26-28.
de Vos S, Forero-Torres A, Ansell SM, Kahl B,
Cheson BD, Bartlet NL, Furman RR, Winter
JN, Kaplan H, Timmerman J, Whiting NC,
Drachman JG, Advani R. A Phase II Study of
Dacetuzumab (SGN-40) in Patients with
Relapsed Diffuse Large B-Cell Lymphoma
(DLBCL) and Correlative Analyses of PatientSpecific Factors. J Hematol Onc. 2014 7:44-53.
Furman RR, Sherman JP, Coutre SE, Cheson
BD, Pagel JM, Hillmen P, Barrientos JC,
Zelenetz AD, Kipps TJ, Flinn I, Ghia P, Eradat H,
Ervin T, Lamanna N, Coiffier B, Pettitt AR, Ma
S, Stilgenbauer S, Cramer P, Aiello M, Johnson
DM, Miller LL, Li D, Jahn TM, Dansey RD,
Hallek M, O’Brien SM. Idelalisib and Rituximab
in Relapsed Chronic Lymphocytic Leukemia.
New Eng J Med. 2014 370(11):997-1007.
Gopal AK, Gooley TA, Rajendran JG, Pagel
JM, Fisher DR, Maloney DG, Appelbaum FR,
Cassaday RD, Shields A, Press OW. Myeloablative I-131-Tositumomab with Escalating Doses
of Fludarabine and Autologous Hematopoietic
Transplantation for Adults Age ≥ 60 Years with
B Cell Lymphoma. Biol Blood Marrow Transplant.
2014 20(6):770-775.
Green DJ, Orgun NN, Jones JC, Hylarides MD,
Pagel JM, Hamlin DK, Wilbur DS, Lin Y, Fisher
DR, Kenoyer AL, Frayo SL, Gopal AK, Orozco
JJ, Gooley TA, Wood BL, Bensinger WI, Press
OW. A preclinical model of CD38-pretargeted
radioimmunotherapy for plasma cell malignancies.
Cancer Res. 2014 74(4):1179-1189.
Mawad R, Gooley TA, Rajendran JG, Fisher
DR, Gopal AK, Shields AT, Sandmaier BM,
Sorror ML, Deeg HJ, Storb R, Green DJ,
Maloney DG, Appelbaum FR, Press OW, Pagel
JM. Radiolabeled Anti-CD45 Antibody with
Reduced-Intensity Conditioning and Allogeneic
Transplantation for Younger Patients with
Advanced Acute Myeloid Leukemia or
Myelodysplastic Syndrome. Biol Blood Marrow
Transplant. 2014 Sep;20(9):1363-8. DOI: 10.
1016/j.bbmt.2014.05.014. Epub 2014 May 20.
Mawad R, Lionberger J, Sandhu R, Gooley TA,
Shannon-Dorcy K, Dean C, Scott B, Sandmaier
BM, O’Donnell P, Becker P, Petersdorf S, Hendrie
P, Sorror ML, Holm N, Deeg J, Appelbaum FR,
Estey EH, Pagel JM. Frequency of Allogeneic
Hematopoietic Cell Transplantation among
Patients with High-or Intermediate-Risk Acute
Myeloid Leukemia in First Complete Remission.
J Clin Oncol. 2013 31(31):3883-3888.
Orozco JJ, Back T, Kenoyer A, Balkin ER, Hamlin
DK, Wilbur DS, Fisher DR, Frayo SL, Hylarides
MD, Green DJ, Gopal AK, Press OW, Pagel JM.
Anti-CD45 Radioimmunotherapy Using 211At
with Bone Marrow Transplantation Prolongs Survival in a Disseminated Murine Leukemia Model.
Blood. 2013 121(18):3759-3767.
Ostronoff F, Othus M, Kantari H, Meshinshi S,
Ravindi F, Hendrie PC, Faderl S, Becker PS,
Cortes J, Pagel JM, Peters S, Godwin J, Willman C, Pierce S, List A, Sandhu V, Walter RB,
Stirewalt DL, Appelbaum F, Chiatovich TJ, Esety EH. A Model for Prediction of FLT3-ITD and
NPM1 (without FLT3-ITD) Positivity in Patients
with Newly Diagnosed Acute Myeloid Leukemia.
Brit J Haematol. 2013 163(1):130-132.
Pagel JM, Spurgeon S, Awan F, Blum K, Lanasa
MC, Flinn IW, Stromatt SC, Byrd JC, Gopal
A. Phase 1 Study of TRU-016, an anti-CD37
SMIPTM protein in relapsed and/or refractory
NHL patients. Brit J Haematol. Forthcoming.
2014 ANNUAL REPORT
Phipps C, Gopal AK, Storer BE, Cassaday RD,
Press OW, Till BG, Pagel JM, Palanca-Wessels
MC, Philip M, Bensinger WI, Holmberg LA,
Shustov AR, Green DJ, Chauncey T, Maloney
DG, Libby EN 3rd. Autologous transplant for
relapsed follicular lymphoma: impact of pretransplant rituximab sensitivity. Leuk Lymphoma.
Epub ahead of print 2014 Apr 8.
Ueda M, Xie H, Sandhu RK, Walter RB, Pagel
JM, Estey EH. Factors associated with early
re-induction chemotherapy for adults with acute
myeloid leukemia. Leuk Lymphoma. 2014 May
31:1-10. Epub ahead of print.
Veatch JR, Sandhu V, Becker PS, Pagel JM,
Appelbaum FR, Estey E. The NCI common
toxicity criteria and treatment-associated
mortality in acute myeloid leukemia. Blood.
2013 122(2):293-294.
Walter RB, Buckley SA, Pagel JM, Wood BL,
Storer BE, Sandmaier BM, Fang M, Gyurkocza
B, Delaney C, Radich JP, Estey EH, Appelbaum
FR. Significance of Minimal Residual Disease
before Myeloablative Allogeneic Hematopoietic
Cell Transplantation for AML in First and
Second Complete Remission. Blood. 2013
122(10):1813-1821.
Walter RB, Gyurkocza B, Storer BE, Godwin
CD, Pagel JM, Buckley SA, Sorror ML, Wood
BL, Storb R, Appelbaum FR, Sandmaier BM.
Comparison of minimal residual disease as
outcome predictor for AML patients in first
complete remission undergoing myeloablative
or nonmyeloablative allogeneic hematopoietic
cell transplantation. Leukemia. Epub ahead of
print 2014 Jun 3.
Neurological Oncology
Cobbs CS. Cytomegalovirus and brain tumor:
epidemiology, biology and therapeutic aspects.
Curr Opin Oncol. 2013 Nov;25(6):682-8.
DOI:10.1097/CCO.0000000000000005. Review.
Cobbs CS. Does valganciclovir have a role
in glioblastoma therapy? Neuro Oncol. 2014
Mar;16(3):330-1. DOI:10.1093/neuonc/nou009.
Cobbs C, Heath J, Stireman JO 3rd, Abbot
P. Carotenoids in unexpected places: gall
midges, lateral gene transfer, and carotenoid
biosynthesis in animals. Mol Phylogenet
Evol. 2013 Aug;68(2):221-8. DOI:10.1016/j.
ympev.2013.03.012. Epub 2013 Mar 27.
Cobbs C, Khan S, Matlaf L, McAllister S, Zider
A, Yount G, Rahlin K, Harkins L, Bezrookove V,
Singer E, Soroceanu L. HCMV glycoprotein B is
expressed in primary glioblastomas and enhances
growth and invasiveness via PDGFR-alpha activation. Oncotarget. 2014 Feb 28;5(4):1091-100.
Cobbs CS, Matlaf L, Harkins LE. Methods for the
detection of cytomegalovirus in glioblastoma cells
and tissues. Methods Mol Biol. 2014; 1119:16596. DOI:10.1007/978-1-62703-788-4_11.
Fontana EJ, Benzinger T, Cobbs C, Henson
J, Fouke SJ. The evolving role of neurological
imaging in neuro-oncology. J Neurooncol. Epub
ahead of print 2014 Aug 1.
Hadaczek P, Ozawa T, Soroceanu L, Yoshida
Y, Matlaf L, Singer E, Fiallos E, James CD,
Cobbs CS. Cidofovir: a novel antitumor agent
for glioblastoma. Clin Cancer Res. 2013 Dec
1;19(23):6473-83. DOI:10.1158/1078-0432.
CCR-13-1121. Epub 2013 Oct 29.
Eric Valliéres, M.D., FRCSC
Thoracic Surgery
Kaplan HG. Vemurafenib Treatment of
V600E-Mutated Malignant Peripheral Nerve
Sheath Tumor. J Natl Comp Can Net. 2013
11:1466-1470.
Matlaf LA, Harkins LE, Bezrookove V, Cobbs
CS, Soroceanu L. Cytomegalovirus pp71
protein is expressed in human glioblastoma
and promotes pro-angiogenic signaling by
activation of stem cell factor. PLoS One.
2013 Jul 5;8(7):e68176. DOI:10.1371/journal.
pone.0068176. Print 2013.
Nassiri F., Scheithauer B.W., Corwin DJ, Kaplan
HG, Mayberg M, Cusimano MD, Rotondo F.,
Kovacs K. Invasive Thymoma Metastatic to the
Cavernous Sinus. Surg Neurol Int. 2031 4:74.
Ulasov I, Yi R, Guo D, Sarvaiya P, Cobbs C. The
emerging role of MMP14 in brain tumorigenesis
and future therapeutics. Biochim Biophys Acta.
2014 Aug;1846(1):113-120. DOI:10.1016/j.
bbcan.2014.03.002. Epub 2014 Mar 19.
Thoracic Oncology
Bakker OJ, van Brunschot S, Farre A, Johnson
CD, Kalfarentzos F, Louie BE, Oláh A, O’Keefe
SJ, Petrov MS, Powell JJ, Besselink MG, van
Santvoort HC, Rovers MM, Gooszen HG. Timing
of enteral nutrition in acute pancreatitis: metaanalysis of individuals using a single-arm of
randomised trials. Pancreatology. PII:S14243903(14)00955-7. DOI:0.1016/j.pan.2014.07.008.
Epub ahead of print 2014 Jul 23.
Bharadwaj SC, Vallières E, Wilshire CL, Blitz
M, Page B, Aye RW, Farivar AS, Louie BE.
Comparison of Preoperative 45 Gy of Radiation
to Higher Dose in Trimodality Management of
Stage IIIA NSCLC. Ann of Thorac Surg. 2014.
Bradley DD, Louie BE, Baik P, Farivar AS,
Aye RW. Assessment and Reduction of Diaphragmatic Tension During Hiatal Hernia Repair.
Surg Endosc. Epub ahead of print 2014 Jul 24.
Bradley DD, Louie BE, Chen J, Aye RW,
McMahon R, Farivar AS. The Effect of Concurrent Esophageal Pathology on Bariatric Surgical
Planning. J Gastrointest Surg. Epub ahead of
print 2014 Sep 12.
Brenner DR, Brennan P, Boffetta P, Amos CI,
Spitz MR, Chen C, Goodman G, Heinrich J,
Bickeböller H, Rosenberger A, Risch A, Muley
T, McLaughlin JR, Benhamou S, Bouchardy C,
Lewinger JP, Witte JS, Chen G, Bull S, Hung
RJ. Hierarchical modeling identifies novel lung
cancer susceptibility variants in inflammation
pathways among 10,140 cases and 11,012
controls. Hum Genet. 2013 132(5):579-89.
Epub 2103 Feb 1. PMCID: PMC3628758.
Cheng TY, King IB, Barnett MJ, Ambrosone
CB, Thornquist MD, Goodman GE, Neuhouser
ML. Serum Phospholipid Fatty Acids, Genetic
Variation in Myeloperoxidase, and Prostate
Cancer risk in Heavy Smokers: A Gene-Nutrient
Interaction in the Carotene and Retinol Efficacy
Trial. Am J Emidemiol. 2013 177(10):1106-17.
Epub 2013 Mar 27. PMCID: PMC3649634.
Cheng TY, Lacroix AZ, Beresford SA, Goodman
GE, Thornquist MD, Zheng Y, Chlebowski RT,
Ho GY, Neuhouser ML. Vitamin D intake and
lung cancer risk in the Women’s Health Initiative.
Am J Clin Nutr. 2013 98(4):1002-11. Epub 2013
Aug 21.
Deen SA, Farivar AS, Louie BE. Thoracic
Techniques: Robotic Thymectomy for Thymoma.
Indian J Surg Oncol. 2013 4(2):132-137.
Deen SA, Kramer JL, Wilshire CL, Vallières E,
Farivar AS, Aye RW, Ely RE, Louie BE. Defining
the Cost of Care for Lobectomy and Segmentectomy: A Comparison of Open, Video Assisted
Thoracoscopic, and Robotic Approaches. Ann
Thorac Surg. 2014 97:1000-7.
27
Doherty JA, Sakoda LC, Loomis MM, Barnett
MJ, Julianto L, Thornquist MD, Neuhouser
ML, Weiss NS, Goodman GE, Chen C. DNA
repair genotype and lung cancer risk in the
beta-carotene and retinol efficacy trial. Int J Mol
Epidemiol Genet. 2013 4(1):11-34. Epub 2013
Mar 18. PMCID: PMC3612452.
Donington J, Vallières E, Bains M, Swisher
S, Pass H. Management of the Apical Tumor:
2013 May 4. Semin Thorac Cardiovasc Surg.
2013 25(3): 256-271.
Farivar AS, Cerfolio R, Vallières E, Knight A,
Bryant A, Lingala V, Aye RW, Louie BE.
Comparing Robotic Lung Resection with
Thoracotomy and VATS Cases Entered into the
STS Database. Innovations. 2014 9:1-15
Farjah F, Varghese TK, Costas K, Krishnadasan
B, Farivar AS, Hubka M, Louie BE, Backhus
LM, Chong N, Gorden J, Cheng AM, He H,
Flum DR, Low D, Aye R, Vallières E, Mulligan
MS, Wood DE. Lung Resection Outcomes and
Costs in Washington State: A Case for Regional
Quality Improvement. Ann Thorac Surg. 2014
98(1):175-182.
Fox MR, Pandolfino JE, Jafari J, Menne D,
Abreu AT, Bogte A, Elvevi A, Ruiz de Leon A,
Kessing BF, Boris L, Remes Troche JM, Gyawali
PC, Wilshire CL, Wasko-Czopnik D, Mion F,
Fruehauf H, Zerbib F, Gellersen O, Heinrich H,
Perez de la Serna J, Sauter MM, Hemmink
GJ, Banasiuk M, Valdovinos MA, Miroslawa U,
Kwiatek MA, Wright J, Weijenborg PW, Sweis
R, Roman S, Vardar R, Ghosh SK, Tutuian
R, Rohof WO, Bredenoord AJ. Inter-observer
agreement for manometry classification of individual swallows and diagnoses using high-resolution manometry (HRM) with esophageal
topography (EPT): results of web-based studies
with high participation. Gastroenterology. 142(5)
Suppl 1:S-34. 2012 DOI:10.1016/S00165085(12)60133-4.
Karp DD, Lee SJ, Keller SM, Wright GS, Aisner
S, Belinsky SA, Johnson DH, Johnston MR,
Goodman G, Clamon G, Okawara G, Marks
R, Frechette E, McCaskill-Stevens W, Lippman
SM, Ruckdeschel J, Khuri FR. A Randomized,
Double-Blind, Placebo-Controlled, Phase III Chemoprevention Trial of Selenium Supplementation
in Patients With Resected Stage I Non-Small-Cell
Lung Cancer: ECOG 5597. J Clin Oncol. 2013
31(33):4179-87. Epub 2013 Sep 3.
Lipham JC, Taiganides PA, Louie BE, Ganz RA,
DeMeester TR. Safety analysis of first 1,000 patients treated with magnetic sphincter augmentation for gastroesophageal reflux disease. Dis
Esophagus. Epub ahead of print 2014 Mar 11.
Louie BE. Endoscopic endoluminal vacuum
therapy in esophageal perforation. Ann Thorac
Surg. 2014 97:1035-6.
Louie BE. Impact of gastropyloric motor activity
on the genesis of reflux esophagitis after an
esophagectomy with gastric tube reconstruction.
Ann Thorac Surg. 2013 96:1838-39.
Louie BE. Robotic Lobectomy for Non-Small
Cell Lung Cancer. Indian J Surg Oncol. 2013
4(2):125-131.
Louie BE. Robotic Lobectomy — The Future
of Minimally Invasive Lobectomy? Clin J Cancer
Res. 2013 25(1):1-3.
Louie BE. Robotic Pneumonectomy. In:
Thoracic Surgery Clinics. Park B editor. 2014
24(2):169-175.
Louie BE. The short-term outcome of threefield minimally invasive esophagectomy for
Siewert type I esophagogastric junctional adenocarcinoma. Ann Thorac Surg. 2013 96:1832.
Louie BE, Farivar AS, Shultz D, Brennan C,
Vallières E, Aye RW. Short Term Outcomes
Comparing Magnetic Sphincter Augmentation
Versus Nissen Fundoplication for Chronic
GERD. Ann Thorac Surg. 2014 98(2).
Louie BE, Gorden J. Endoscopic one-way
valve implantation in patients with prolonged air
leak and the use of digital air leak monitoring.
Ann Thorac Surg. 2013 95:1249-1250.
Louie BE, Kapur S, Blitz M, Farivar AS,
Vallières E, Aye RW. Length and Pressure of
the Reconstructed Lower Esophageal Sphincter
is Determined by Both Crural Closure and
Nissen Fundoplication. J Gastrointest Surg.
2013 17(2):236-243.
Niebisch S, Wilshire CL, Peters JH. Systematic
analysis of esophageal pressure topography
in high-resolution manometry of 68 normal
volunteers. Dis Esophagus. 2013 26:651-660.
Qureshi AP, Aye RW, Buduhan G, Knight A,
Orlina J, Farivar AS, Wagner OJ, McHugh S,
Louie BE. The Laparoscopic Nissen-Hill Hybrid:
Pilot Study of a Combined Anti-Reflux Procedure.
Surgical Endosc. 2013 27(6):1945-1952.
Sin DD, Tammemagi CM, Lam S, Barnett MJ,
Duan X, Tam A, Auman H, Feng Z, Goodman
GE, Hanash S, Taguchi A. Pro-Surfactant
Protein B as a Biomarker for Lung Cancer
Prediction. J Clin Oncol. 2013 31(36):4536-43.
Epub 2013 Nov 18.
Vallières E. Oligometastatic NSCLC: the
changing role of surgery. Transl Lung Cancer
Res. 2014 3(3): 192-4.
Wang Y, McKay JD, Rafnar T, Wang Z, Timofeeva MN, Broderick P, Zong X, Laplana M, Wei
Y, Han Y, Lloyd A, Delahaye-Sourdeix M, Chubb
Hunt BM, Horton MP, Vallières E. Bronchogenic
Carcinoid Tumors that are 18F-Fluorodeoxyglucose Avid on Positron Emission Tomography Accepted by Eur J Cardio-Thorac 2013 44(4): 1-4.
Hunt BM, Louie BE, Dunst CM, Lipham JC,
Farivar AS, Sharata A, Aye RW. Esophagectomy for Failed Endoscopic Therapy in Patients
with High Grade Dysplasia or Intramucosal
Carcinoma. Dis Esophagus. 2014 27(4):362-67.
Hunt BM, Louie BE, Schembre DB, Bohorfoush AG, Farivar AS, Aye RW. Outcomes in
Patients Who Failed Endoscopic Therapy for
Dysplastic Barrett’s or Early Esophagus Cancer.
Ann Thorac Surg. 2013 95:1734-1740.
Johnson CS, Louie BE, Wille A, Dunst CM, Worrell SG, DeMeester SR, Reynolds J, Dixon J, Lipham JC, Lada M, Peters JH, Watson TJ, Farivar
AS, Aye RW. The Durability of Endoscopic
Therapy for Treatment of Barrett’s Metaplasia,
Dysplasia and Mucosal Cancer after Nissen
Fundoplication. J Gastrointest Surg. 2014.
Jutric Z, Louie BE. Laparoscopic Paraesophageal Hernia Repair. Surg Laparosc Endosc
Percutan Tech. 2013 23(5):436-41.
Brian Lee, M.D., Ph.D.
Radiation Oncology
28
2014 ANNUAL REPORT
Gulsuner S, Walsh T, Watts AC, Lee MK,
Thornton AM, Casadei S, Rippey C, Shahin
H; Consortium on the Genetics of Schizophrenia, Dobie DJ, PAARTNERS Study Group,
Nimgaonkar VL, Go RC, Savage RM, Swerdlow
NR, Gur RE, Braff DL, King MC, McClellan
JM. Spatial and temporal mapping of de novo
mutations in schizophrenia to a fetal prefrontal
cortex network. Cell. 2013 Aug 1;154(3):51829. DOI:10.1016/j.cell.2013.06.049.
Tsuang DW, Esterberg M, Braff D, Calkins M,
Cadenhead K, Dobie D,Freedman R, Green
MF, Greenwood T, Gur R,Gur,R, Horan W,
Lazzeroni LC, Light GA, Millard SP, Olincy A,
Neuchterlein K, Seidman L,Siever L, Silverman
J, Stone W, Sprock J, Sugar C, Swerdlow N,
Tsuang M, Turetsky B, Radant A. Is there an association between advanced paternal age and
endophenotype deficit levels in schizophrenia?
PLoS One. 2014 Feb 11. DOI:10.1371/journal.
pone.0088379.
Nursing
Art Therapy
D, Gaborieau V, Wheeler W, Chatterjee N, Thorleifsson G, Sulem P, Liu G, Kaaks R, Henrion
M, Kinnersley B, Vallée M, LeCalvez-Kelm F,
Stevens VL, Gapstur SM, Chen WV, Zaridze D,
Szeszenia-Dabrowska N, Lissowska J, Rudnai
P, Fabianova E, Mates D, Bencko V, Foretova L,
Janout V, Krokan HE, Gabrielsen ME, Skorpen F,
Vatten L, Njølstad I, Chen C, Goodman G, Benhamou S, Vooder T, Välk K, Nelis M, Metspalu
A, Lener M, Lubiński J, Johansson M, Vineis P,
Agudo A, Clavel-Chapelon F, Bueno-de-Mesquita HB, Trichopoulos D, Khaw KT, Johansson M,
Weiderpass E, Tjønneland A, Riboli E, Lathrop
M, Scelo G, Albanes D, Caporaso NE, Ye Y, Gu
J, Wu X, Spitz MR, Dienemann H, Rosenberger A, Su L, Matakidou A, Eisen T, Stefansson
K, Risch A, Chanock SJ, Christiani DC, Hung
RJ, Brennan P, Landi MT, Houlston RS, Amos
CI. Rare variants of large effect in BRCA2 and
CHEK2 affect risk of lung cancer. Nat Genet.
2014 July;46(7):736-41. Epub ahead of print
2014 Jun 1.
Wechsler ME, Laviolette M, Rubin AS, Fiterman
J, Lapa e Silva JR, Shah PL, Fiss E, Olivenstein
R, Thomson NC, Niven RM, Pavord ID, Simoff
M, Hales JB, McEvoy C, Slebos D, Holmes M,
Phillips MJ, Erzurum SC, Hanania NA, Sumino
K, Kraft M, Cox G, Sterman DH, Hogarth K,
Kline JN, Mansur AH, Louie BE, Leeds WM,
Barbers RG, Austin JHM, Shargill NS, Quiring J,
Armstrong B, Castro M. Bronchial Thermoplasty - Long Term Safety and Effectiveness in Patients with Severe Persistent Asthma. J Allergy
Clin Immunol. 2013 132(6):1295-1302.
Wilshire CL, Kaufer JW, Gorea HR, Sauer
JS, Knight PA. Healing study of porcine heart
transapical wounds closed using a remote
automated suturing technology. Innovations.
2013 8:50-55.
Wilshire CL, Louie BE, Manning KA, Horton
MP, Castiglioni M, Aye RW, Farivar AS,
Gorden J, Vallières E. CT evaluation of adenocarcinomas is highly predictive of oncologic
outcome at resection. J Thorac Oncol. 2014.
Wilshire CL, Salvador R, Sepesi B, Niebisch
S, Watson TJ, Litle VR, Peyre CG, Jones CE,
Peters JH. A novel method for the diagnosis of
reflux-related respiratory symptoms: normalization of reflux-associated oxygen desaturations
following Nissen fundoplication and establishment of normal values. J Gastrointest Surg.
2013 17:30-38.
Wilson JL, Bradley DD, Louie BE, Vallières
E, Aye RW, Farivar AS. Laparoscopy with Left
Chest Collis Gastroplasty. CTSNet.org: Thoracic
Expert Techniques. Ferguson M editor. 2014
June 5.
Wilson JL, Louie BE, Cerfolio RJ, Park BJ, Vallières E, Aye RW, Abdel-Razek AM, Bryant AS,
Farivar AS. The Prevalence of Nodal Upstaging
During Robotic Lung Resection in Early Stage
Non-Small Cell Lung Cancer (NSCLC). Ann
Thorac Surg. 2014 97:1901-7.
Wilson JL, Louie BE, Farivar AS, Vallières E,
Aye RW. Fully Covered Self-Expanding Removable Metal Stents Are Effective For Benign
Esophagogastric Disruptions and Strictures. J
Gastrointest Surg. 2013 17:2045-2050.
Wilson JL, BE Louie. New Options for the
Management of GERD. In: Current Surgery
Reports (2). Yang SC, DeMeester S editors.
2014 2(6):57-67.
Supportive Care Services
Greenwood TA, Swerdlow NR, Gur RE, Cadenhead KS, Calkins ME, Dobie DJ, Freedman R,
Green MF, Gur RC, Lazzeroni LC, Nuechterlein KH, Olincy A, Radant AD, Ray A, Schork
NJ, Seidman LJ, Siever LJ, Silverman JM,
Stone WS, Sugar CA, Tsuang DW, Tsuang MT,
Turetsky BI, Light GA, Braff DL. Genome-wide
linkage analyses of 12 endophenotypes for
schizophrenia. Consortium on the Genetics
of Schizophrenia. Am J Psychiatry. 2013
170(5):521-32.
Thompson N. Chemotherapy and Biotherapy
drugs for Autoimmune Disease: New biotherapy
drugs and older chemotherapy agents may improve quality of life in patients with autoimmune
diseases. Am Nurse Today. 2013 8(9). 22-27.
Thompson N. The Pathway to Becoming a
Professional Nurse. Clin J Oncol Nurs. 2013 17(6),
673-674.
Other
Cheng TY, Millen AE, Wactawski-Wende J,
Beresford SA, Lacroix AZ, Zheng Y, Goodman
GE, Thornquist MD, Neuhouser ML. Vitamin D
Intake Determines Vitamin D Status of Postmenopausal Women, Particularly Those with Limited
Sun Exposure. J Nutr. 2014 144(5):681-9. Epub
2014 Mar 5.
Phillips M, Byrnes R, Cataneo RN, Chaturvedi
A, Kaplan PD, Libardoni M, Mehta V, Mundada M, Patel U, Ramakrishna N, Schiff PB,
Zhang X. Detection of volatile biomarkers
of therapeutic radiation in breath. J Breath
Res. 2013 7(3):036002. DOI:10.1088/17527155/7/3/036002.
Swain SM, Ward JC. Drug Discount Program.
JAMA 2013 310:15 1626-1627.
Ward JC. Oncology Reimbursement in the Era
of Personalized Medicine and Big Data. J Oncol
Pract 2014 10:2 83-86.
Ward JC. Policy Statement on the 340B Drug
Pricing Program by the American Society of
Clinical Oncology. J Oncol Pract. Epub ahead of
print 2014 Apr 15.
Ward JC. Potential Approaches to Sustainable,
Long-Lasting Payment Reform in Oncology. J
Oncol Pract. Epub ahead of print 2014 Apr 15.
29
2014 Cancer Committee
Ralph Aye, M.D.
Cancer Physician Liaison/QI Coordinator/
Thoracic Surgery
ColoRectal Surgery
David Beatty, M.D.
Informatics Committee
Thomas Brown, M.D., MBA
Cancer Program Administrator
SCI Executive Director
Lara Ragsdale, R.D.
Nutrition Services
Gordon Irving, M.D.
Pain Management Services
Robert Resta, M.S., CGC
Genetic Counseling
Sandra Johnson, LISCW
Manager, Oncology Social Work
Carlotta Reynolds, BSN, R.N.
Oncology Nursing
Mary Kelly, M.D.
Diagnostic Radiology
Mariko Tameishi
Manager, Personalized Medicine Program
Barbara Kollar, MHA, MCHES
Director, SCI Supportive Care Services
Nancy Thompson, R.N., MSN, AOCNS
Clinical Director, SCI Performance
and Quality
Candy Bonham, CTR
Cancer Program Coordinator
Cancer Registry Supervisor
Kenneth Kraemer, M.D.
Medical Oncology
Christopher Cannon, M.D.
Musculoskeletal Surgery
Daniel Labriola, N.D.
Naturopathic Services
Andy Case, MSN, R.N., OCN
Director, Medical Oncology
Shannon Marsh
American Cancer Society
Dan Veljovich, M.D.
Clinical Program Leader,
Gynecologic Oncology Surgery
Janice Connolly, M.D.
Palliative Care Services
Becky Mann, MSN, R.N., OCN
Oncology Nursing
Tanya Wahl, M.D.
Medical Oncology
Patricia Dawson, M.D., Ph.D.
Medical Director, SCI Breast Program/
Chief of Breast Surgery
Karen McInerney, R.T.
Director, Women’s Cancer Center Network
Danielle Westley
Medical Education Department
Representative
Nici Eaton
American Cancer Society Representative
Philip Gold, M.D.
Medical Oncology/Director,
Clinical Research
John Henson, M.D.
Neuro-Oncology
Patra Grevstad, R.N., M.N.
Manager, Clinical Research
30
Marc Horton, M.D.
General Surgery
Vivek Mehta, M.D.
Radiation Oncology
Michael Milder, M.D.
Hematology/Medical Oncology
Paul Myoung, MHA, M.A.
Performance Improvement
Becca Parkins, M.A., M.Div., BCC
Pastoral Care
Ronald Tickman, M.D.
Pathology
Chairman, Cancer Committee
John Wynn, M.D.
Psychosocial Oncology Program
Cancer Program Administrator
SCI Vice President of Operations
David Zucker, M.D., Ph.D.
Rehabilitation Services
James Porter, M.D.
Urologic Surgery
2014 ANNUAL REPORT
Swedish Cancer Institute Members
Kathy Adamson, M.D.
Carolyn Anderson, ARNP
Torrance Andrews, M.D.
Karlee Ausk, M.D.
Ralph Aye, M.D.
Melissa Hayes Balmadrid, M.D.
Dae Hee Bang, M.D.
Todd Barnett, M.D.
Darlene Barr, M.D.
Tara Benkers, M.D.
Anna Berry, M.D.
Kevin Beshlian, M.D.
George Birchfield, M.D.
Amy BonDurant, M.D.
James Borrow, M.D.
Jack Brandabur, M.D.
Thomas D Brown, M.D., MBA
Sally Browning, M.D.
Claire Buchanan, M.D.
Christopher Cannon, M.D.
Christopher Carlson, M.D.
Phillip Chapman, M.D.
Trang Chau, ARNP
Jey-Hsin Chen, M.D.
Martha Clay, ARNP
Charles Cobbs, M.D., Ph.D.
Carol Cornejo, M.D.
David J. Corwin, M.D.
Betsey Cotter, M.D.
Patricia Dawson, M.D., Ph.D.
Heidi Dishneau, ARNP
Dorcas Dobie, M.D.
David Dong, M.D.
Robert Douglas, M.D.
Charles Drescher, M.D.
Mariann Drucker, M.D.
Michelle Eden, M.D.
Paul Edmonson, M.D.
Erin Ellis, M.D.
Stephen Eulau, M.D.
Alex Farivar, M.D.
Joelle Thirsk Fathi, DNP, ARNP
Robert Feldman, M.D.
Mehmet Fer, M.D.
Michael Florence, M.D.
Daniel Flugstad, M.D.
Sarah Fouke, M.D.
James Gasparich, M.D.
Patricia Geraghty, M.D.
Timothy Gleason, M.D.
Philip Gold, M.D.
Sheldon Goldberg, M.D.
Gary Goodman, M.D.
Jed Gorden, M.D.
Margaret Gorham, ARNP
Helene Gracie, ARNP
Thomas Green, M.D.
Tom Green, MSN, ARNP
Douglas Grier, M.D.
Paula Hallam, M.D.
Steven Han, M.D.
James Hanson, M.D.
Nancy Hanson, CGC
Kurt Harmon, M.D.
Jason Harper, M.D.
Marquis Hart, M.D.
Melinda Hawkins, M.D.
Eric Heinberg, M.D.
Karen Hendershott, M.D.
John Henson IV, M.D.
Genee Holtzman, ARNP
Marc Horton, M.D.
Matthew Horton, M.D.
Donald Howard, M.D., Ph.D.
Charles Hunter, M.D.
LuLu Iles-Shih, M.D.
Christina Isacson, M.D.
Smita Jain, M.D.
Eileen Johnston, M.D.
Matthew Johnston, M.D.
Carolyn Jordan, M.D.
Thomas Jurich, M.D.
Hank Kaplan, M.D.
Mary Kelly, M.D.
Bart Keogh, M.D., Ph.D.
Namou Kim, M.D.
Carolyn Kitchell, M.D.
Kenneth Kraemer, M.D.
Rodney Kratz, M.D.
Bup-Jong Jennif Kum, M.D.
Dan Labriola, N.D.
Daniel Landis, M.D., Ph.D.
Brian Lee, M.D.
Christine Lee, M.D.
Douglas Lee, M.D.
Edward Lee, M.D.
Ellyn Lee, M.D.
Thomas K. Lee, M.D.
Pamela Li, M.D.
Joel Lilly, M.D.
Skyler Lindsley, M.D.
Brandon Liu, M.D.
Christopher Loiselle, M.D.
Brian Louie, M.D., MHA, MPH
Steven Macfarlane, M.D.
John Maldazys, M.D.
Katherine Mandell, M.D.
Kristin Manning, M.D.
Kristin Mantei, M.D.
Daniel Markowitz, M.D.
Ryan Martinez, M.D.
Timonthy Mate, M.D.
Raya Mawad, M.D.
Vivek Mehta, M.D.
Robert Meier, M.D.
Raman Menon, M.D.
Michael Milder, M.D.
Wandra Miles, M.D.
Rajnish Mishra, M.D.
Loulie Molloy, M.D.
Susan Montgomery, M.D.
David Moore, M.D., MBA
Astrid Morris, M.D.
John Mullen, M.D.
Christine Mullins, M.D.
Laura Nason, M.D.
Erik Ness, M.D.
David Omdal, M.D.
Evan Ong, M.D., M.S.
Robert Osnis, M.D.
John Pagel, M.D., Ph.D.
Keith Paige, M.D.
Pamela Paley, M.D.
Melanie Panchal, ARNP
Min Park, M.D.
David Patterson, M.D.
Nuria Periz-Reyes, M.D.
Mary Lee Peters, M.D.
William Peters III, M.D.
Ellen Pizer, M.D.
Darren Pollock, M.D.
James Porter, M.D.
Andrew F. Precht, M.D.
Josh Press, M.D.
Leslie Price, M.D.
Nicholas Procaccini, M.D.
Amarnath Ramakrishnan, M.D.
Rostislav Ranguelov, M.D.
Joseph Rank, M.D.
Beth Ann Reimel, M.D.
Robert Resta, MS, CGC
Kristine Rinn, M.D.
Jeffrey Robin, P.A.
Timothy Roddy, M.D.
James Rogers, M.D.
Eric Rosen, M.D.
Marc Rosenshein, M.D.
Steven Rostad, M.D.
Marco Salazar, M.D.
Drew Schembre, M.D.
Udo Schmiedl, M.D., Ph.D.
Chirag Shah, M.D., MPH
Jennifer Shook, M.D.
Michelle Sinnett, M.D.
Joseph Sniezek, M.D.
James Spiegel, M.D.
Somasundaram Subramaniam, M.D., M.S.
Robert Takamiya, M.D.
Lisa Thomassen, M.D.
Sean Thornton, M.D.
Ronald Tickman, M.D.
Shannon Tierney, M.D.
Andrew Ting, M.D.
M. Christine Tiu, PA-C
Samuel Tolman, M.D.
Erik Torgerson, M.D.
John Travaglini, M.D.
John Tschirhart, M.D.
Eric Vallières, M.D.
Daniel Veljovich, M.D.
Sandra Vermeulen, M.D.
Pooja Voria, M.D.
Tanya Wahl, M.D.
Nan Ping Want, M.D.
Jeff Ward, M.D.
Reid Weiss, ARNP
Sean Wells, M.D.
Howard West, M.D.
Kathy Witmer, DNP, ARNP
John Wynn, M.D.
Danbin Xu, M.D., Ph.D.
Edwin Yau, M.D.
Ronald Young, M.D.
Song Zhao, M.D., Ph.D.
David Zucker, M.D., Ph.D.
31
Swedish Cancer Institute Administrative Team
Vice President for Operations, SCI
Maya Abboud-Finch, BSN, R.N., OCN
Manager
Radiation Therapy Nursing & Support
Brad Alexander, MBA
Director of Finance, SMG
Aliki Birkenbuel, MHSA
Manager
SCI Edmonds
Karyn Blasi, MBA
Manager
SCI Breast Imaging Services Operations
Candy Bonham, CTR
Supervisor
Registry
Andy Case, MSN, R.N.
Director
Medical Oncology
Amy Christian, MSN, R.N., OCN
Manager
SCI Issaquah & East Side
Susan Christian, BSN, R.N., OCN
Supervisor
SCI Edmonds
Linda Cole, BSN, R.N., OCN
Manager
First Hill Treatment Center
Teresa Coluccio, M.N., R.N., CBCN
Manager
SCI Multidisciplinary Breast Clinic
Darlene Fanus, RTRM
Manager
Mobile Mammography Program & SCI
Breast Screening Network
Karen McInerney, RTRM
Director
True Family Women’s Cancer Center &
Breast Care Network
Lisa Fraser, M.A.
Administrative Assistant to Cindy Kearney,
Karen McInerney, Barbara Kollar and Andy
Case
Victoria Miles
Director of Development
Swedish Medical Center Foundation
Patra Grevstad, M.N., R.N.
Manager
Research Administration
Denise Gwinn
Manager
Thoracic, Colon & Rectal, and Head & Neck
Clinics
Clay Holtzman
Media Relations Manager, Swedish
Rhonda Jack, MHA
Manager
First Hill & Ballard Medical Oncology
Sandra Johnson, MSW, LICSW
Manager
Oncology Social Work
Cindy Kearney, RT(T)
Director
Radiation Therapy and Network & Cancer
Treatment Centers
Erin Kieper
Business Development Specialist, Senior
Kylie Davidson, MPH, CHES
Supervisor
Supportive Care Network & Affiliate Services
Barbara Kollar, MHA
Director
Supportive Care Network & Affiliate
Services, Thoracic, Colon & Rectal, and
Head & Neck Clinics
Selin Demir
Project Manager
Swedish Cancer Institute Administration
Jennifer Lamharzi, BSN, R.N., OCN
Manager
First Hill Treatment Center
Lauren Moore
Assistant Director, Major Gifts
Swedish Medical Center Foundation
Craig Munos
Chief Marketing & Communication Officer,
Swedish
Dimitri Pletz, MBA
Senior Financial Analyst
Swedish Health Services
Jill Sato
Marketing and Communication Director,
Swedish
David Shepard, Ph.D.
Director
Medical Physics & Dosimetry
Melinda Stewart
Supervisor
Breast Imaging Support Functions
Nancy Thompson, MSN, R.N.
Clinical Director
Quality & Performance
Mariko Tameishi, MHA
Program Manager
Personalized Medicine Program
Erin Verginia
Executive Assistant to Dr. Thomas Brown
and Jim Yates
Cecilia Willard
Supervisor
SCI Edmonds
Jeffery Lewis, R.T.(R)(T)
Manager
Radiation Oncology Operations
32
2014 ANNUAL REPORT
The SCI Network of Distributed Expertise
The Swedish Cancer Institute
(SCI) network distributes
cancer-care, by some of the
nation’s leading experts, to
ensure patients are able to
receive care near where they
live and work. Through its five
hospital-based, multidisciplinary cancer programs and
four freestanding clinics, SCI
is bringing much-needed
screenings, diagnostics and
therapies to communities
throughout the Greater Puget
Sound region.
The SCI at First Hill in Seattle was the
first location at Swedish offering cancer
services. Many highly sophisticated and
technologically advanced surgical procedures, radiation treatments and systemic
therapies, as well as clinical trials and
supportive care, are offered at First Hill.
From First Hill, the SCI network initially
grew to include additional sites in the
central Seattle area, including:
• The Swedish Radiosurgery Center at
Cherry Hill, which is the only location in
the Pacific Northwest that offers both
CyberKnife® and Gamma Knife® stereotactic radiosurgery platforms. Cherry Hill
is also the site of the Ben & Catherine
Ivy Center for Advanced Brain Tumor
Treatment at the Swedish Neuroscience
Institute.
•The community-based Radiation
Treatment Center at Swedish Ballard,
in which SCI installed the first TomoTherapy® Hi-Art® system in the Seattle
metropolitan area. The Ballard campus
also includes a state-of-the-art infusion
center, which opened in 2013 and also
provides access to clinical trials.
Swedish Mill Creek
(Breast Imaging, Colorectal Cancer Care)
SCI at Swedish Edmonds
SCI at Swedish Ballard
SCI at Swedish First Hill
Swedish Cherry Hill
SCI Radiosurgery Center
en and Catherine Ivy Center for
B
Advanced Brain Tumor Treatment
Swedish Redmond
(Breast Imaging, Colorectal Cancer Care)
SEATTLE
BELLEVUE
BURIEN
SCI Eastside Hematology/Oncology
SCI at Swedish Issaquah
SCI at Highline Medical Center/
Franciscan Health Services
(Radiation Oncology)
During the last two years, there has been
considerable growth at SCI Edmonds,
including the addition of colon and rectal
surgery, and a clinic dedicated to high-risk
screening and genetic counseling. A new
building, which opened in 2013, allows
convenient access to physician, laboratory
and systemic therapy services, as well as
an expanded clinical trials program, for
patients who live north of Seattle. SCI
Edmonds also undertook a major renovation
of its existing radiation oncology facility in
2014, which included the installation of the
newest generation of linear accelerator.
At SCI, services and sustained quality are
intrinsically linked. This foundational focus
on quality at SCI Edmonds was again
recognized in 2014 through a successful
Quality Oncology Practice Initiative (QOPI)
evaluation and silver-level commendation
by the American College of Surgeons’
Commission on Cancer.
The Swedish Cancer Institute at Swedish
Issaquah has been providing the eastside
community cancer-care services, along
with local access to clinical trials, since it
first opened its doors in 2011. Today SCI
has a robust presence at the Swedish
Issaquah campus, including significant
growth in the breast, colorectal, gynecologic, head & neck, thoracic and urologic
cancer programs. SCI at Issaquah also
offers local access to colorectal, high-risk
breast and lung cancer screenings, rehabilitation, systemic therapy, radiation therapy,
naturopathic services, and 3D digital
mammography with tomosynthesis.
The SCI Network enables the delivery of
personalized medicine, making it possible
for SCI cancer-care teams to provide the
right treatment at the right time and in the
right place, closest to where patients live
and work. For more information about
becoming part of the SCI Network,
please contact 206-386-3476 or
[email protected].
Arnold Pavilion
1221 Madison St.
Seattle, WA 98104
NON PROFIT
U.S. POSTAGE
PAID
SEATTLE, WA
PERMIT NO. 1564

2014 Swedish Cancer Institute (SCI)

Transcription

Similar documents

Svensk-Tysk Ordbok (Swedish Edition) - My

Customer`s recommendations using the SCI technology:

Making entrepreneurship easy

scandi candy shops

40 Years of Spinal Cord Injury Research

TCD-SCSS-T.20141120.004 Accession Date: 20-Nov

Read an extract of the report

the 2009 donzi 43 zr

to view the complete brochure

Winter 2013 - Scandinavian